# Inspiratory Muscle Training in COPD

Renata I N Figueiredo, Aline M Azambuja, Felipe V Cureau, and Graciele Sbruzzi

BACKGROUND: The benefits of inspiratory muscle training (IMT) for patients with COPD are documented in the literature, but its isolated effect or association with other interventions, the best training methods, and what type of patient benefits the most are not clear. We sought to assess the effects of IMT on respiratory muscle strength, pulmonary function, dyspnea, functional capacity, and quality of life for subjects with COPD, considering IMT isolated or association with other interventions, presence of inspiratory muscle weakness, training load, and intervention time. METHODS: We searched the MEDLINE, EMBASE, PEDro, Cochrane CENTRAL, and LILACS databases in June 2018. We also performed a manual search of references in the studies found in the database search and included in this analysis. We included randomized controlled trials that investigated the abovementioned outcomes and assessed IMT, either isolated or associated with other interventions, in comparison with a control group, placebo, or other interventions, in subjects with COPD. We used the GRADE approach to evaluate the quality of the evidence. RESULTS: Of 1,230 search results, 48 were included (N = 1,996 subjects). Isolated IMT increased P<sub>Imax</sub> (10.64 cm H<sub>2</sub>O, 95% CI 7.61– 13.66), distance walked in 6-min-walk test (34.28 m; 95% CI 29.43-39.14), and FEV<sub>1</sub> (0.08, 95% CI 0.02–0.13). However, there was no improvement in dyspnea and quality of life. The presence of inspiratory muscle weakness did not change the results; higher loads (60-80% of P<sub>Imax</sub>) promoted a greater improvement in these outcomes, and a shorter intervention time (4 weeks) improved  $P_{Imax}$ but longer intervention times (6-8 weeks) are required to improve functional capacity. IMT associated with other interventions only showed an increase in P<sub>Imax</sub> (8.44 cm H<sub>2</sub>O; 95% CI 4.98–11.91), and the presence of inspiratory muscle weakness did not change this result. CONCLUSIONS: Isolated IMT improved inspiratory muscle strength, functional capacity, and pulmonary function, without changing dyspnea and quality of life. Associated IMT only increased inspiratory muscle strength. These results indicate that isolated IMT can be considered as an adjuvant intervention in patients with COPD. Key words: breathing exercises; COPD; dyspnea; physical capacity; respiratory *muscle training*. [Respir Care 0;0(0):1–•. © 0 Daedalus Enterprises]

### Introduction

COPD is one of the major causes of chronic morbidity and mortality worldwide.<sup>1</sup> Prognosis of patients with COPD is influenced by the severity and recurrence of exacerbation, with yearly mortality rates of 11% for patients who need hospitalization, 5–50% for patients on mechanical ventilation, and rising as high as 37% in case of hospitalization for exacerbation recurrence.<sup>2</sup> Strategies are required that aim to reduce the disease progression and thus improve patients' prognosis as well as reduce costs of health care and the global and socioeconomic burden of the disease.<sup>3</sup>

Ms Figueiredo, Ms Azambuja, and Ms Sbruzzi are affiliated with the Postgraduate Program in Pneumological Sciences, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil. Dr Cureau is affiliated with the Postgraduate Program in Endocrinology, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil. Ms Sbruzzi is affiliated with the Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil.

Ms Figueiredo presented a version of this paper at the Universidade Federal do Rio Grande do Sul, in November 2018, in Porto Alegre, Brazil.

This study was supported by the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior. The authors have disclosed no conflicts of interest.

Supplementary material related to this paper is available at http://www.rcjournal.com.

Individuals with COPD present with limitations in exercise capacity due to multiple factors, including ventilation, gas exchange, cardiovascular disease,<sup>4</sup> and abnormalities in peripheral muscles.<sup>5</sup> Inspiratory muscle dysfunction also occurs in these patients and is associated with dyspnea and reduced exercise capacity.<sup>6,7</sup> Thus, pulmonary rehabilitation is recommended as an efficient intervention in cardiorespiratory management, generating improvements in exercise performance, with reductions in dyspnea in patients with different degrees of disease severity.<sup>8</sup> As a pulmonary rehabilitation strategy, inspiratory muscle training (IMT) optimizes lung capacity and, consequently, improves physical conditioning.<sup>9</sup>

Gosselink et al<sup>10</sup> conducted a systematic review with meta-analysis, including 32 randomized controlled trials (RCTs) on IMT effects in subjects with COPD. The authors made general and subgroup analyses with regard to training modality (strength of resistance and if pulmonary rehabilitation was added) and subject characteristics. The authors concluded that IMT improves inspiratory muscle strength, functional capacity, dyspnea, and quality of life. In subjects with inspiratory muscle weakness, inclusion of IMT in pulmonary rehabilitation programs improved inspiratory muscle strength and tended to improve exercise performance.<sup>10</sup>

Recently, Beaumont et al<sup>11</sup> published a new systematic review on the subject. The authors reviewed 43 studies (37 meta-analyses), including RCTs, nonrandomized controlled trials, and observational studies published until 2017, and they noted the effects of IMT when isolated or associated with pulmonary rehabilitation, considering the presence of respiratory muscle weakness. They observed that IMT improved inspiratory muscle strength, quality of life, exercise capacity, and dyspnea, although there was no additional effect on pulmonary rehabilitation. According to the authors, the presence of respiratory muscle weakness seemed not to affect results, although they suggest further investigations of this intervention regarding dyspnea and quality of life.

Based on the results reported by Gosselink et al<sup>10</sup> and Beaumont et al,<sup>11</sup> a new systematic review including only RCTs and approaching important clinical issues for this type of training and this type of population is necessary. This systematic review will assess IMT effects on respiratory muscle strength, pulmonary function, dyspnea, functional capacity, and quality of life in patients with COPD, considering 4 factors: (1) IMT isolated or associated to other interventions; (2) the presence of inspiratory muscle weakness; (3) training load; and (4) intervention time.

## Methods

This systematic review and meta-analysis followed recommendations proposed by the Cochrane Collaboration<sup>12</sup> and the PRISMA Statement.<sup>13</sup> The study protocol was registered in PROSPERO (CRD42017080337).

# **Eligibility Criteria**

We included RCTs that assessed the effect of IMT, whether isolated or associated with other interventions, that compared treated subjects with a control group (ie, no intervention), placebo, or other intervention (eg, pulmonary rehabilitation, exercise, breathing exercises, or usual care); subject criteria included a diagnosis of COPD by spirometry, consistent with the GOLD criteria (FEV<sub>1</sub>/FVC < 70%), during both exacerbation and out-patient clinic care. The following outcomes were considered: respiratory muscle strength, pulmonary function, functional capacity, dyspnea, and quality of life. Studies with incomplete data or lacking data description were excluded.

### Search Strategy

We searched the following electronic databases: MEDLINE (accessed via PubMed), EMBASE, Cochrane CENTRAL, PEDro, and LILACS. A manual search was also conducted in references of studies already published on the subject. The research terms used individually or combined include "pulmonary disease, chronic obstructive" (MeSH and entry terms) and "breathing exercises" (MeSH and entry terms) associated with a list of sensitive terms for searches of RCTs as prepared by Robinson and Dickersin.<sup>14</sup> There were no restrictions as to year and language. The search occurred in June 2018. The full search strategy used for PubMed can be seen in supplementary materials at http://www.rcjournal.com.

### **Selection of Studies and Data Extraction**

The titles and abstracts of all papers identified with the search strategy were independently assessed by 2 reviewers with a checklist containing inclusion and exclusion criteria. Studies that did not meet the eligibility criteria were excluded, and those that met the criteria or raised questions were selected for assessment of the whole text. The same independent reviewers assessed and selected these articles. Disagreements between reviewers were resolved by consensus. When the studies did not present the data required for meta-analysis, the corresponding author was contacted. In cases when the data were not available, the paper was excluded from the study. Data were extracted through a standardized form containing information on the methodological characteristics of the studies, subjects, interventions,

Correspondence: Graciele Sbruzzi PT ScD, Rua Felizardo, n° 750, Jardim Botânico, Porto Alegre 90690200, Brazil. E-mail: graciele.sbruzzi@ufrgs.br.

DOI: 10.4187/respcare.07098

Copyright (C) 2020 Daedalus Enterprises ePub ahead of print papers have been peer-reviewed, accepted for publication, copy edited and proofread. However, this version may differ from the final published version in the online and print editions of RESPIRATORY CARE

and outcomes. The outcomes extracted were: respiratory muscle strength (ie, maximum inspiratory pressure  $[P_{Imax}]$  and maximum expiratory pressure), pulmonary function, (FVC, vital capacity, and FEV<sub>1</sub>), functional capacity (ie, distance walked in the 6-min-walk test [6MWT] and maximum oxygen consumption  $[\dot{V}_{O_2}]$ ), dyspnea (Borg scale), and quality of life (St George Respiratory Questionnaire score).

# **Risk of Bias Assessment**

The risk of bias was assessed independently by 2 reviewers using the Cochrane Collaboration tool, considering the following characteristics for all included studies: generation of appropriate sequence, allocation concealment, patient and therapist blinding, description of losses and exclusions, and analysis of intention to treat. Studies without clear descriptions of these items were considered not clear or not informed.

### **Data Analysis**

The meta-analysis was conducted using the randomeffects model, and the effect size used was the mean difference, determined by the difference between the means at the baseline moment and at the end of the study for each group. These data were expressed as weighted mean differences among groups and standard deviation of the difference.<sup>13</sup> A 95% CI was considered statistically significant. Statistical homogeneity across studies was assessed using the inconsistency test (I<sup>2</sup>), where values > 25% and > 50%were considered to indicate moderate and high heterogeneity, respectively.<sup>15</sup> All analyses were made using Review Manager 5.3 (Cochrane Collaboration) and Stata 14 (StataCorp, College Station, Texas). Heterogeneity across studies was explored with 2 strategies: (1) executing the meta-analysis again, removing 1 paper at a time to check whether any individual study explained heterogeneity; (2) sensitivity analyses to assess sub-groups of studies with higher probability of producing valid intervention estimates, based on relevant prespecified clinical information that influence IMT effects on results (eg, association of interventions with IMT, intervention duration, inspiratory load, and whether the studies included patients with inspiratory muscle weakness, denoted as  $P_{Imax} < 60 \text{ cm H}_2\text{O}$ ). In addition, meta-regression analyses were performed for outcome with high number of studies included (ie, P<sub>Imax</sub> and 6MWT) and including main covariates (ie, inspiratory load, intervention duration, and weakness).

# Summary of Evidence: GRADE Criteria

The quality of the evidence was assessed using the GRADE approach, as recommended by the Cochrane

Handbook for Systematic Reviews of Interventions (Internet tool available at https://gradepro.org).<sup>12</sup> For each outcome, the quality of the evidence was based on 5 factors: risk of bias; inconsistency; indirectness; imprecision; and potential for publishing bias. Quality was reduced by one level for each factor not met. The GRADE approach resulted in 4 levels of evidence quality: high, moderate, low, and very low.<sup>16</sup>

### Results

### **Description of the Studies**

The search strategy resulted in 1,230 abstracts, of which 112 were considered potentially relevant and were selected for detailed analysis. A total of 48 studies met the eligibility criteria and were included in the systematic review and in the meta-analysis (N = 1,996 subjects) (Fig. 1); 39 studies (n =943 subjects) only assessed isolated IMT.<sup>17-55</sup> Of these, 25 studies (n = 631 subjects) included subjects with respiratory muscle weakness.<sup>17-19,22-28,31-34,37,38,40,41,43,45-49,52</sup> Various loads for IMT were 15% of  $P_{Imax}$ , <sup>42,46,48</sup> 30% of  $P_{Imax}$ , <sup>17,28,31,33,38,40,43,51</sup> load progression of 5–35% of  $P_{Imax}$ , <sup>23,24</sup> load progression up to 40–50% of  $P_{Imax}$ ,<sup>21,39,53</sup> load progression up to 60% of  $P_{Imax}$ ,<sup>41,39,53</sup> load progression up to 60% of  $P_{Imax}$ ,<sup>42,20,22,24-28,30,34,37,45,47,49,50,52,54-56</sup> 70% of  $P_{Imax}$ ,<sup>44</sup> and 80% of PImax.36 Belman et al19 and Oh35 used PFLEX equipment, and the load used for IMT was not clear. Leelarungrayub et al<sup>32</sup> used Portex equipment, and load/resistance was set by the tube diameter (ie, 6 mm, 4 mm, and 2 mm) (can be seen in supplementary materials at http://www. rcjournal.com).

Nine studies (n = 965 subjects) assessed IMT in association with some other type of intervention.<sup>57-65</sup> These other interventions were pulmonary rehabilitation,<sup>58,62,64,65</sup> resistance/aerobic training with cycle ergometer,<sup>59-61,63</sup> or conventional physical therapy.<sup>57</sup> In 4 studies (n = 153 subjects), the associated IMT was conducted in subjects with respiratory muscle weakness.<sup>57,58,60,63</sup> The loads used for IMT associated with other interventions varied: 30% of P<sub>Imax</sub>,<sup>59,63</sup> 30–60% of P<sub>Imax</sub>,<sup>61,62,64,65</sup> 70% of P<sub>Imax</sub>,<sup>58,60</sup> and 60–80% of P<sub>Imax</sub>.<sup>57</sup> For isolated IMT, most studies used IMT with low or no load, and the control group was IMT placebo. For studies that assessed IMT in association with another intervention, most studies used low-load IMT or pulmonary rehabilitation as control groups (can be seen in supplementary materials at http://www.rcjournal.com).

## **Risk of Bias**

Of the studies included in this systematic review, 15.2% reported allocation concealment, 17.4% reported blinding of therapists, and 30.4% used the principle of intention to treat for statistical analyses, characterizing a high risk of bias for these items. Still, 34.8% used patient blinding, and




Fig. 1. Flow chart. IMT = inspiratory muscle training.

39.1% used blinding for outcome appraisers, which carry moderate bias risk. Finally, 80.4% of the included studies described losses in follow-up and exclusions, and 65.2% reported randomization in subject assignment, which carry moderate risk of bias (see the supplementary materials at http://www.rcjournal.com).

### **Effects of Interventions**

Maximum Inspiratory Pressure. Of the 39 papers included that conducted isolated IMT, 36 studies<sup>17-27,29-34,36-41,43-55</sup> assessed  $P_{Imax}$  (n = 889 subjects). Significant improvement occurred in PImax when IMT was compared to the control groups (10.64 cm H<sub>2</sub>O, 95% CI 7.61–13.66, I<sup>2</sup>: 46%) (Fig. 2). Based on the GRADE approach, the quality of evidence for this result was considered low due to methodological limitations, imprecision, and inconsistency of results (Table 1). Considering the 24 studies that only included subjects with inspiratory muscle weakness,<sup>17-19,22-27,31-34,37,38,40,41,43,45-49,52</sup> there was significant improvement for this outcome (9.60 cm H<sub>2</sub>O, 95% CI 5.74–13.46, I<sup>2</sup>: 40%). In addition, considering studies that included subjects without respiratory muscle weakness, 20,21,29,30,36,39,44,50,51,53-55 significant improvement was also observed for this outcome (13.61 cm H<sub>2</sub>O, 95% CI 12.45–14.78, I<sup>2</sup>: 0%). The assessment of studies that used up to 35% of PImax training loads showed improvement in this outcome (8.30 cm H<sub>2</sub>O, 95% CI 1.38-15.21,  $I^2$ : 0%); the same behavior was observed for loads between 40% and 50% (11.20 cm H<sub>2</sub>O, 95% CI 5.86–16.54, I<sup>2</sup>: 0%), and a slightly superior gain was observed for loads between 60% to 80% of P<sub>Imax</sub> (10.99 cm H<sub>2</sub>O, 95% CI 6.65–15.33, I<sup>2</sup>: 68%). Gains observed with shorter intervention times were equivalent to gains obtained with longer interventions:  $\leq 4$  weeks (11.62 cm H<sub>2</sub>O, 95% CI 5.32–17.91, I<sup>2</sup>: 0%); 6–8 weeks (11.69 cm H<sub>2</sub>O, 95% CI 5.03–26.47, I<sup>2</sup>: 39%); 16 weeks (15.75 cm H<sub>2</sub>O, 95% CI 5.03–26.47, I<sup>2</sup>: 0%); and no difference was observed for 10 weeks and 12 weeks (8.84 cm H<sub>2</sub>O, 95% CI –0.71 to 18.39, I<sup>2</sup>: 66%). When included in meta-regression, these covariates were not significantly associated with the heterogeneity observed through the studies (data not shown).

In the analysis of studies that assessed IMT associated with other interventions, we identified 8 papers<sup>57-60,62-65</sup> that assessed  $P_{Imax}$  (n = 985 subjects), and significant improvement was observed in this outcome (8.44 cm H<sub>2</sub>O, 95% CI 4.98–11.91, I<sup>2</sup>: 0%) (Fig. 3). The quality of evidence was considered moderate based on methodology limitations, imprecision, and inconsistency of results (Table 1). Considering the 4 studies that only included subjects with inspiratory muscle weakness<sup>57,58,60,63</sup> (8.44 cm H<sub>2</sub>O, 95%) CI 0.60–16.28, I<sup>2</sup>: 0%) and studies including subjects without respiratory muscle weakness (8.46 cm H<sub>2</sub>O, 95% CI 4.58–12.34,  $I^2$ : 0%), there was significant improvement in both situations. Studies that used IMT loads between 60% and 80% of P<sub>Imax</sub> obtained significant improvement (10.08 cm H<sub>2</sub>O, 95% CI 1.05–19.11, I<sup>2</sup>: 0%). Significant improvement in P<sub>Imax</sub> was also observed in studies with interventions that lasted 3-4 weeks (8.51 cm H<sub>2</sub>O, 95% CI 4.59-12.42, I<sup>2</sup>: 0%) and 10-12 weeks (10.97 cm H<sub>2</sub>O, 95% CI 0.95–20.99, I<sup>2</sup>: 0%).

FVC. We identified 10 studies<sup>18,19,24,26,32,33,39,52,53,55</sup> that conducted isolated IMT and assessed FVC, and no significant improvement was observed (-0.28, 95% CI -0.62 to 0.07,  $I^2$ : 85%) (see the supplementary materials at http:// www.rcjournal.com). Based on the GRADE approach, the quality of evidence for this result was very low due to methodology limitations and inconsistency of results (Table 1). No change in this result was found for the 6 studies that only included patients with inspiratory muscle weakness<sup>18,19,26,32,33,52</sup> (-0.10, 95% CI -0.42 to 0.23,  $I^2$ : 42%), and the same occurred for subjects without respiratory weakness (-0.62, 95% CI -2.01 to 0.77, I<sup>2</sup>: 94%). In the analysis of IMT loads up to 35% of  $P_{Imax}$ (-0.04, 95% CI -0.92 to 0.84, I<sup>2</sup>: 0%) and intervention durations of 4-5 weeks (-1.22, 95% CI -6.17 to 3.72,  $I^2$ : 0%) and 6-8 weeks (-0.30, 95% CI -0.68 to 0.07,  $I^2$ : 90%), no significant difference was observed between IMT and controls.

**FEV<sub>1</sub>.** We identified 10 studies<sup>18,19,24,26,29,32,42,52,53,55</sup> that conducted isolated IMT and assessed FEV<sub>1</sub> (n = 259

Copyright (C) 2020 Daedalus Enterprises ePub ahead of print papers have been peer-reviewed, accepted for publication, copy edited and proofread. However, this version may differ from the final published version in the online and print editions of RESPIRATORY CARE

	SD To	tal	Mean	SD	Total V	Veight, %	Mean Difference IV, Random, 95% CI	Mean Difference IV, Random, 95% Cl
	22.4	9	3.2	3.1	9	2.9	9.00 (-5.77 to 23.77)	
							, , ,	
							· · · /	<del></del>
		12	-4	19				
4 3	33.9	6	4	19.8	5	0.8	0.00 (-32.20 to 32.20)	
11	42	10	3.9	36.8	9	0.7	7.10 (-28.34 to 42.54)	
30.6 2	23.8	10	2	21	10	1.9	28.60 (8 93 to 48.27)	
30.6 2	23.8	10	2	20.9	10	1.9	28.60 (8 97 to 48.23)	
18 2	24.3	16	5.2	26.6	17	2.3	12.80 (-4.57 to 30.17)	+
	25.2	10	10.6	27.2	10	1.5	16.20 (-6.78 to 39.18)	
					18		4.00 (-21.53 to 29.53)	
								<del></del>
								T
								_T
								<u> </u>
			3.2	10.6				
				13.4				+
		10	-1.8	22	10	2.0	23.40 (4.51 to 42.29)	
5.3 2	28.5	15	5.3	22.07	16	2.2	0.00 (-18.03 to 18.03)	-+-
25.2	15.8	10	14.3	14.2	10	3.4	10.90 (-2.27 to 24.07)	+
30.3 4	40.4	12	3.1	28.6	12	1.0	27.20 (-0.81 to 55.21)	
12.4 1	16.4	11	24	5.8	4	4.1	-11.60 (-22.84 to -0.36)	
							( ,	+
							( ,	
		19	7.6	10.8	21	7.0	0.90 (-5.10 to 6.90)	
		13	1.0	10.0			( )	
df = 35 ( <i>P</i> = .	4	52 = 46%	%		437	100	10.64 (7.61 to 13.66)	00 -50 0 50 10
df = 35 ( <i>P</i> = .	4: .002); I <sup>2</sup> =	= 46%			437	100	-	Favors control Favors IMT
df = 35 ( <i>P</i> = .	4! .002); I <sup>2</sup> =	= 46%		Control SD		100 Veight, %	_	
df = 35 ( <i>P</i> = . Exp	4! .002); I <sup>2</sup> =	= 46%	C					Favors control Favors IMT Mean Difference
df = 35 ( <i>P</i> = . Exp	4: .002);   <sup>2</sup> = perimenta SD To	= 46%	( Mean					Favors control Favors IMT Mean Difference
df = 35 ( <i>P</i> = . Exp Mean 17.6	4: .002);   <sup>2</sup> = perimenta SD To	= 46%	Mean 2.2	SD 15.8	Total V 28	Veight, % 45.3	Mean Difference IV, Random, 95% CI 15.40 (7.47 to 23.33)	Favors control Favors IMT Mean Difference IV, Random, 95% Cl
df = 35 (P = . Exp Mean 17.6 5 3	4: .002); I <sup>2</sup> = berimenta <u>SD To</u> 14.2 : 31.9	= 469 ll otal 27 9	0 Mean 2.2 12	SD 15.8 32.6	Total V 28 7	Veight, % 45.3 2.8	Mean Difference IV, Random, 95% CI 15.40 (7.47 to 23.33) -7.00 (-38.90 to 24.90)	Favors control Favors IMT Mean Difference IV, Random, 95% Cl
df = 35 ( <i>P</i> = . Exp Mean 17.6 5 2 18 2	4: .002); I <sup>2</sup> = berimenta <u>SD To</u> 14.2 : 31.9 24.3	= 46% btal 27 9 16	0 Mean 2.2 12 5.2	SD 15.8 32.6 26.6	Total V 28 7 17	Veight, % 45.3 2.8 9.5	Mean Difference IV, Random, 95% Cl 15.40 (7.47 to 23.33) -7.00 (-38.90 to 24.90) 12.80 (-4.57 to 30.17)	Favors control Favors IMT Mean Difference IV, Random, 95% Cl
df = 35 (P = . Exp Mean 17.6 5 3 18 2 26.8 2	4: .002); I <sup>2</sup> = berimenta <u>SD To</u> 14.2 : 31.9 24.3 25.2	= 469 btal 27 9 16 10	0 Mean 2.2 12 5.2 10.6	SD 15.8 32.6 26.6 27.2	Total V 28 7 17 10	Veight, % 45.3 2.8 9.5 5.4	Mean Difference IV, Random, 95% Cl 15.40 (7.47 to 23.33) -7.00 (-38.90 to 24.90) 12.80 (-4.57 to 30.17) 16.20 (-6.78 to 39.18)	Favors control Favors IMT Mean Difference IV, Random, 95% Cl
df = 35 (P = . Exp Mean 17.6 5 26.8 26.8 32 2	4: .002); I <sup>2</sup> = berimenta <u>SD To</u> 14.2 : 31.9 24.3 25.2 23.3	= 46% btal 27 9 16 10	0 Mean 2.2 12 5.2 10.6 19	SD 15.8 32.6 26.6 27.2 32.2	Total V 28 7 17 10 9	Veight, % 45.3 2.8 9.5 5.4 4.4	Mean Difference IV, Random, 95% CI 15.40 (7.47 to 23.33) -7.00 (-38.90 to 24.90) 12.80 (-4.57 to 30.17) 16.20 (-6.78 to 39.18) 13.00 (-12.52 to 38.52)	Favors control Favors IMT Mean Difference IV, Random, 95% Cl
df = 35 (P = . Exp Mean 17.6 5 26.8 2 32 21 1 2 1	4: .002);   <sup>2</sup> = berimenta <u>SD To</u> 14.2 31.9 24.3 25.2 23.3 23.3	= 469 btal 27 9 16 10 10 12	0 Mean 2.2 12 5.2 10.6 19 5	SD 15.8 32.6 26.6 27.2 32.2 10.6	Total V 28 7 17 10 9 8	Veight, % 45.3 2.8 9.5 5.4 4.4 12.5	Mean Difference IV, Random, 95% CI 15.40 (7.47 to 23.33) -7.00 (-38.90 to 24.90) 12.80 (-4.57 to 30.17) 16.20 (-6.78 to 39.18) 13.00 (-12.52 to 38.52) 6.00 (-9.09 to 21.09)	Favors control Favors IMT Mean Difference IV, Random, 95% Cl
df = 35 (P = . Exp Mean 17.6 3 26.8 32 32 11 9.61 2	4: .002);   <sup>2</sup> = berimenta SD To 14.2 : 31.9 24.3 25.2 23.3 23.3 23.3 22.3 :	Il otal 27 9 16 10 10 12 21	0 Mean 2.2 12 5.2 10.6 19 5 2.1	SD 15.8 32.6 26.6 27.2 32.2 10.6 27.5	Total V 28 7 17 10 9 8 18	Veight, % 45.3 2.8 9.5 5.4 4.4 12.5 11.3	Mean Difference IV, Random, 95% Cl 15.40 (7.47 to 23.33) -7.00 (-38.90 to 24.90) 12.80 (-4.57 to 30.17) 16.20 (-6.78 to 39.18) 13.00 (-12.52 to 38.52) 6.00 (-9.09 to 21.09) 7.51 (-8.38 to 23.40)	Favors control Favors IMT Mean Difference IV, Random, 95% Cl
df = 35 (P = . Exp Mean 17.6 3 26.8 32 32 11 9.61 2	4: .002);   <sup>2</sup> = Derimenta SD To 14.2 : 31.9 24.3 25.2 23.3 22.3 : 28.5	il otal 27 9 16 10 12 21 15	0 Mean 2.2 12 5.2 10.6 19 5	SD 15.8 32.6 26.6 27.2 32.2 10.6	Total V 28 7 17 10 9 8 18 16	Veight, % 45.3 2.8 9.5 5.4 4.4 12.5 11.3 8.8	Mean Difference IV, Random, 95% Cl 15.40 (7.47 to 23.33) -7.00 (-38.90 to 24.90) 12.80 (-4.57 to 30.17) 16.20 (-6.78 to 39.18) 13.00 (-12.52 to 38.52) 6.00 (-9.09 to 21.09) 7.51 (-8.38 to 23.40) 1.80 (-16.24 to 19.84)	Favors control Favors IMT Mean Difference IV, Random, 95% Cl
df = 35 (P = . Exp Mean 17.6 5 26.8 32 32 11 9.61 5.3 2	4: .002);   <sup>2</sup> = Derimenta SD To 14.2 : 31.9 24.3 25.2 23.3 23.3 22.3 : 28.5 1:	Il otal 27 9 16 10 10 12 21	0 Mean 2.2 12 5.2 10.6 19 5 2.1	SD 15.8 32.6 26.6 27.2 32.2 10.6 27.5	Total V 28 7 17 10 9 8 18	Veight, % 45.3 2.8 9.5 5.4 4.4 12.5 11.3	Mean Difference IV, Random, 95% Cl 15.40 (7.47 to 23.33) -7.00 (-38.90 to 24.90) 12.80 (-4.57 to 30.17) 16.20 (-6.78 to 39.18) 13.00 (-12.52 to 38.52) 6.00 (-9.09 to 21.09) 7.51 (-8.38 to 23.40)	Favors control Favors IMT Mean Difference IV, Random, 95% Cl
df = 35 (P = . Exp Mean 17.6 3 26.8 32 32 11 9.61 2	4: .002);   <sup>2</sup> = Derimenta SD To 14.2 : 31.9 24.3 25.2 23.3 23.3 22.3 : 28.5 1:	il otal 27 9 16 10 12 21 15	0 Mean 2.2 12 5.2 10.6 19 5 2.1	SD 15.8 32.6 26.6 27.2 32.2 10.6 27.5	Total V 28 7 17 10 9 8 18 16	Veight, % 45.3 2.8 9.5 5.4 4.4 12.5 11.3 8.8	Mean Difference IV, Random, 95% Cl 15.40 (7.47 to 23.33) -7.00 (-38.90 to 24.90) 12.80 (-4.57 to 30.17) 16.20 (-6.78 to 39.18) 13.00 (-12.52 to 38.52) 6.00 (-9.09 to 21.09) 7.51 (-8.38 to 23.40) 1.80 (-16.24 to 19.84)	Favors control Favors IMT Mean Difference IV, Random, 95% Cl
df = 35 (P = . Exp Mean 17.6 5 26.8 32 32 11 9.61 5.3 2	4: .002);   <sup>2</sup> = Derimenta SD To 14.2 : 31.9 24.3 25.2 23.3 23.3 22.3 : 28.5 1:	il otal 27 9 16 10 12 21 15	0 Mean 2.2 12 5.2 10.6 19 5 2.1	SD 15.8 32.6 26.6 27.2 32.2 10.6 27.5	Total V 28 7 17 10 9 8 18 16	Veight, % 45.3 2.8 9.5 5.4 4.4 12.5 11.3 8.8	Mean Difference IV, Random, 95% Cl 15.40 (7.47 to 23.33) -7.00 (-38.90 to 24.90) 12.80 (-4.57 to 30.17) 16.20 (-6.78 to 39.18) 13.00 (-12.52 to 38.52) 6.00 (-9.09 to 21.09) 7.51 (-8.38 to 23.40) 1.80 (-16.24 to 19.84)	Favors control Favors IMT Mean Difference IV, Random, 95% Cl
df = 35 (P = . Exp Mean 17.6 5 3 18 2 26.8 2 32 2 11 2 9.61 2 5.3 2 = 7 (P = .75);	4: .002);   <sup>2</sup> = berimenta <u>SD To</u> 14.2 : 31.9 24.3 25.2 23.3 23.3 23.3 23.3 23.3 ;   <sup>2</sup> = 0%	el de la constante de la const	(Mean 2.2 12 5.2 10.6 19 5 2.1 3.5	SD 15.8 32.6 26.6 27.2 32.2 10.6 27.5 22.1	Total V 28 7 17 10 9 8 18 16 113	Veight, % 45.3 2.8 9.5 5.4 4.4 12.5 11.3 8.8 100	Mean Difference IV, Random, 95% CI 15.40 (7.47 to 23.33) -7.00 (-38.90 to 24.90) 12.80 (-4.57 to 30.17) 16.20 (-6.78 to 39.18) 13.00 (-12.52 to 38.52) 6.00 (-9.09 to 21.09) 7.51 (-8.38 to 23.40) 1.80 (-16.24 to 19.84) 11.20 (5.86 to 16.54)	Favors control Favors IMT Mean Difference IV, Random, 95% Cl
df = 35 (P = . Exp Mean 17.6 5 18 26.8 2 11 26.8 32 11 29.61 5.3 2 11 2 9.61 2 5.3 2 12 2 2 12 2 12 2 2 12 2 12 1	4: .002);   <sup>2</sup> = berimenta <u>SD To</u> 14.2 : 31.9 24.3 25.2 23.3 23.3 23.3 23.3 23.3 23.3 23	e 469 btal 27 9 16 10 10 12 21 15 20	0 Mean 2.2 12 5.2 10.6 19 5 2.1 3.5 3.2	SD 15.8 32.6 26.6 27.2 32.2 10.6 27.5 22.1 3.1	Total V 28 7 17 10 9 8 18 16 113 9 9	Veight, % 45.3 2.8 9.5 5.4 4.4 12.5 11.3 8.8 100 4.9	Mean Difference IV, Random, 95% Cl 15.40 (7.47 to 23.33) 7.00 (-38.90 to 24.90) 12.80 (-4.57 to 30.17) 16.20 (-6.78 to 39.18) 13.00 (-12.52 to 38.52) 6.00 (-9.09 to 21.09) 7.51 (-8.38 to 23.40) 1.80 (-16.24 to 19.84) 11.20 (5.86 to 16.54) 9.00 (-5.77 to 23.77)	Favors control Favors IMT Mean Difference IV, Random, 95% Cl
df = 35 (P = . Exp Mean 17.6 26.8 22.8 26.8 20.	4: .002);   <sup>2</sup> = berimenta SD To 14.2 : 31.9 24.3 25.2 23.3 22.3 : 28.5 : ;   <sup>2</sup> = 0% 22.4 28.1	e 469 lotal 27 9 16 10 12 21 15 20 9 13	0 Mean 2.2 12 5.2 10.6 19 5 2.1 3.5 3.2 8.2	SD 15.8 32.6 26.6 27.2 32.2 10.6 27.5 22.1 3.1 18	Total V 28 7 17 10 9 8 18 16 113 9 9 12	Veight, % 45.3 9.5 5.4 4.4 12.5 11.3 8.8 100 4.9 3.7	Mean Difference IV, Random, 95% Cl 15.40 (7.47 to 23.33) -7.00 (-38.90 to 24.90) 12.80 (-4.57 to 30.17) 16.20 (-6.78 to 39.18) 13.00 (-12.52 to 38.52) 6.00 (-9.09 to 21.09) 7.51 (-8.38 to 23.40) 1.80 (-16.24 to 19.84) 11.20 (5.86 to 16.54) 9.00 (-5.77 to 23.77) 17.20 (-1.16 to 35.56)	Favors control Favors IMT Mean Difference IV, Random, 95% Cl
df = 35 (P = . Exp Mean 17.6 5 18 2 26.8 32 32 11 5.3 2 5.3 2 = 7 (P = .75); 12.2 25.4 29.8 3 2 29.8 3 2 2 2 2 2 2 2 3 2 2 2 2 2 2 2 2 2 2 2 2 2	4: .002);   <sup>2</sup> = berimenta <u>SD To</u> 14.2 : 31.9 24.3 25.2 23.3 23.3 23.3 23.3 23.3 : ;   <sup>2</sup> = 0% 22.4 28.1 32.5 :	e 469 lotal 27 9 16 10 12 21 15 20 9 13 21	Mean 2.2 12 5.2 10.6 19 5 2.1 3.5 3.5 3.2 8.2 3.1	SD 15.8 32.6 26.6 27.2 32.2 10.6 27.5 22.1 3.1 18 28.6	Total V 28 7 17 10 9 8 18 16 113 9 12 21	Veight, % 45.3 2.8 9.5 5.4 4.4 12.5 11.3 8.8 100 4.9 3.7 3.7	Mean Difference IV, Random, 95% CI 15.40 (7.47 to 23.33) -7.00 (-38.90 to 24.90) 12.80 (-4.57 to 30.17) 16.20 (-6.78 to 39.18) 13.00 (-12.52 to 38.52) 6.00 (-9.09 to 21.09) 7.51 (-8.38 to 23.40) 1.80 (-16.24 to 19.84) 11.20 (5.86 to 16.54) 9.00 (-5.77 to 23.77) 17.20 (-1.16 to 35.56) 26.70 (8.18 to 45.22)	Favors control Favors IMT Mean Difference IV, Random, 95% Cl
df = 35 (P = . Exp Mean 17.6 5 3 18 2 26.8 32 2 11 2 9.61 2 5.3 2 = 7 (P = .75); 12.2 2 25.4 2 29.8 3 21.3 2	4: .002);   <sup>2</sup> = berimenta <u>SD To</u> 14.2 : 31.9 24.3 25.2 23.3 23.3 23.3 22.3 : ;   <sup>2</sup> = 0% 22.4 28.5 : ;   <sup>2</sup> = 0%	e 469 bital 27 9 16 10 10 12 21 15 20 9 13 21 8	Mean 2.2 12 5.2 10.6 19 5 2.1 3.5 3.2 8.2 3.2 3.2 5	SD 15.8 32.6 26.6 27.2 32.2 10.6 27.5 22.1 3.1 18 28.6 21.4	Total V 28 7 17 10 9 8 18 16 113 9 12 21 9	Veight, % 45.3 2.8 9.5 5.4 4.4 12.5 11.3 8.8 100 4.9 3.7 3.7 3.8	Mean Difference IV, Random, 95% CI 15.40 (7.47 to 23.33) -7.00 (-38.90 to 24.90) 12.80 (-4.57 to 30.17) 16.20 (-6.78 to 39.18) 13.00 (-12.52 to 38.52) 6.00 (-9.09 to 21.09) 7.51 (-8.38 to 23.40) 1.80 (-16.24 to 19.84) 11.20 (5.86 to 16.54) 9.00 (-5.77 to 23.77) 17.20 (-1.16 to 35.56) 26.70 (6.18 to 45.22) 16.30 (-1.59 to 34.19)	Favors control Favors IMT Mean Difference IV, Random, 95% Cl
df = 35 (P = . Exp Mean 17.6 5 18 26.8 2 11 26.8 2 11 2 9.61 2 5.3 2 11 2 2 5.3 2 12 2 2 5.4 2 2 13 2 2 14 2 2 2 2 3 2 2 15 2 18 2 2 18 2 2 18 2 2 18 2 2 18 2 2 18 2 2 18 2 12 2 18 18 18 18 18 18 18 18 18 18	4: .002);   <sup>2</sup> = berimenta <u>SD To</u> 14.2 : 31.9 24.3 25.2 23.3 23.3 23.3 22.3 : ;   <sup>2</sup> = 0% 22.4 28.1 32.5 : 16.1 16	e 469 bital 27 9 16 10 10 12 21 15 20 9 13 21 8 12	C Mean 2.2 12 5.2 10.6 19 5 2.1 3.5 3.2 8.2 3.1 5 -4	SD 15.8 32.6 26.6 27.2 32.2 10.6 27.5 22.1 3.1 18 28.6 21.4 19	Total V 28 7 17 10 9 8 18 16 113 9 12 21 9 15	Veight, % 45.3 9.5 5.4 4.4 12.5 11.3 8.8 100 4.9 3.7 3.7 3.7 3.8 5.5	Mean Difference IV, Random, 95% Cl 15.40 (7.47 to 23.33) -7.00 (-38.90 to 24.90) 12.80 (-4.57 to 30.17) 16.20 (-6.78 to 39.18) 13.00 (-12.52 to 38.52) 6.00 (-9.09 to 21.09) 7.51 (-8.38 to 23.40) 1.80 (-16.24 to 19.84) 11.20 (5.86 to 16.54) 9.00 (-5.77 to 23.77) 17.20 (-1.16 to 35.56) 26.70 (8.18 to 45.22) 16.30 (-1.59 to 34.19) 15.00 (1.79 to 28.21)	Favors control Favors IMT Mean Difference IV, Random, 95% Cl
df = 35 (P = . Exp Mean 17.6 26.8 22.2 11 9.61 25.3 2 12.2 25.4 29.8 21.3 25.4 29.8 21.3 11 30.6 2 2 2 2 2 2 2 3 2 2 2 3 2 2 2 3 2 2 3 2 2 3 2 2 3 2 2 3 2 2 3 2 2 3 3 2 3 3 2 3 3 3 3 3 3 3 3 3 3 3 3 3	4: .002);   <sup>2</sup> = berimenta SD To 14.2 : 31.9 24.3 25.2 23.3 22.3 : 28.5 : ;   <sup>2</sup> = 0% 22.4 28.1 32.5 : 16.1 32.5 : 16.2 16 23.8	e 469 l ottal 27 9 16 10 12 21 15 20 9 13 21 8 12 10 13 21 13 21 12 13 21 12 13 21 12 13 21 12 13 21 12 13 21 12 13 21 12 12 13 21 13 21 13 21 13 21 13 21 13 12 13 12 13 12 13 12 13 12 13 12 13 12 13 12 13 12 13 12 13 12 13 12 13 12 13 12 13 12 13 12 13 12 13 13 13 13 13 13 13 13 13 13	( <u>Mean</u> 2.2 12 5.2 10.6 19 5 2.1 3.5 3.2 8.2 3.1 5 -4 2	SD 15.8 32.6 27.2 32.2 10.6 27.5 22.1 3.1 18 28.6 21.4 19 21	Total V 28 7 17 10 9 8 18 16 113 9 12 21 9 12 21 9 15 10	Veight, % 45.3 2.8 9.5 5.4 4.4 12.5 11.3 8.8 100 4.9 3.7 3.7 3.7 3.7 3.8 5.5 3.4	Mean Difference IV, Random, 95% Cl 15.40 (7.47 to 23.33) -7.00 (-38.90 to 24.90) 12.80 (-4.57 to 30.17) 16.20 (-6.78 to 39.18) 13.00 (-12.52 to 38.52) 6.00 (-9.09 to 21.09) 7.51 (-8.38 to 23.40) 1.80 (-16.24 to 19.84) 11.20 (5.86 to 16.54) 9.00 (-5.77 to 23.77) 17.20 (-1.16 to 35.56) 26.70 (8.18 to 45.22) 16.30 (-1.59 to 34.19) 15.00 (1.79 to 28.21) 28.60 (8.93 to 48.27)	Favors control Favors IMT Mean Difference IV, Random, 95% Cl
df = 35 (P = . Exp Mean 17.6 5 18 2 26.8 2 32 11 5.3 2 5.3 2 5.3 2 5.3 2 2 5.3 2 2 5.4 2 2 5.4 2 2 2 5.4 2 2 2 5.4 2 2 5.4 2 2 5.4 2 2 5.3 2 2 5.3 2 2 5.3 2 2 5.3 2 2 5.3 5.3 2 5.3 5.3 2 5.3 2 5.3 5.3 2 5.3 5.3 5.3 5.3 5.3 5.3 5.3 5.3	$\begin{array}{c} 4:\\ .002);  ^2 =\\ \hline \text{Derimenta}\\ SD To\\ 14.2 ::\\ 31.9 :\\ 24.3 :\\ 25.2 :\\ 23.3 :\\ 23.3 :\\ 23.3 :\\ 23.3 :\\ 23.3 :\\ 23.3 :\\ 23.3 :\\ 15.1 :\\ 16.1 :\\ 16 :\\ 23.8 :\\$	e 469 l ottal 27 9 16 10 12 21 15 20 9 13 21 8 12 10 10 11 10 12 13 21 10 10 10 10 10 10 10 10 10 1	( <u>Mean</u> 2.2 12 2 5.2 10.6 19 5 2.1 3.5 3.2 8.2 3.1 5 -4 2 2	SD 15.8 32.6 26.6 27.2 32.2 10.6 27.5 22.1 3.1 18 28.6 21.4 19 21.4 20.9	Total V 28 7 17 10 9 8 18 16 113 9 12 21 9 12 21 9 15 10 10	Veight, % 45.3 2.8 9.5 5.4 4.4 12.5 11.3 8.8 100 4.9 3.7 3.7 3.7 3.8 5.5 4 3.4	Mean Difference IV, Random, 95% Cl 15.40 (7.47 to 23.33) -7.00 (-38.90 to 24.90) 12.80 (-4.57 to 30.17) 16.20 (-6.78 to 39.18) 13.00 (-12.52 to 38.52) 6.00 (-9.09 to 21.09) 7.51 (-8.38 to 23.40) 1.80 (-16.24 to 19.84) 11.20 (5.86 to 16.54) 9.00 (-5.77 to 23.77) 17.20 (-1.16 to 35.56) 26.70 (8.18 to 45.22) 16.30 (-1.59 to 34.19) 15.00 (1.79 to 28.21) 28.60 (8.93 to 48.27) 28.60 (8.93 to 48.27)	Favors control Favors IMT Mean Difference IV, Random, 95% Cl
df = 35 (P = . Exp Mean 17.6 5 26.8 2 9.61 2 5.3 2 11 2 25.4 2 29.8 2 21.3 11 30.6 2 30.6 2 2 2 2 2 2 2 2 2 2 2 2 2	4: .002);   <sup>2</sup> = berimenta <u>SD To</u> 14.2 : 31.9 24.3 25.2 23.3 23.3 23.3 22.3 : ;   <sup>2</sup> = 0% 22.4 28.5 : ;   <sup>2</sup> = 0% 22.4 28.1 5 : ;   <sup>2</sup> = 0%	a definition of the second sec	Mean           2.2           12           5.2           10.6           19           5           2.1           3.5           3.2           8.2           3.1           5           -4           2           7	SD 15.8 32.6 26.6 27.2 32.2 10.6 27.5 22.1 3.1 18 28.6 21.4 19 21 20.9 21.9	Total V 28 7 17 10 9 8 18 16 113 9 12 21 9 15 10 10 12	Veight, % 45.3 2.8 9.5 5.4 4.4 12.5 11.3 8.8 100 4.9 3.7 3.7 3.7 3.8 5.5 3.4 3.4 3.3	Mean Difference IV, Random, 95% Cl 15.40 (7.47 to 23.33) -7.00 (-38.90 to 24.90) 12.80 (-4.57 to 30.17) 16.20 (-6.78 to 39.18) 13.00 (-12.52 to 38.52) 6.00 (-9.09 to 21.09) 7.51 (-8.38 to 23.40) 1.80 (-16.24 to 19.84) 11.20 (5.86 to 16.54) 9.00 (-5.77 to 23.77) 17.20 (-1.16 to 35.56) 26.70 (8.18 to 45.22) 16.30 (-1.59 to 34.19) 15.00 (1.79 to 28.21) 28.60 (8.97 to 48.23) 5.00 (-15.08 to 25.08)	Favors control Favors IMT Mean Difference IV, Random, 95% Cl
df = 35 (P = . Exp Mean 17.6 5 18 26.8 2 11 26.8 2 11 2 9.61 2 5.3 2 11 2 25.4 2 21.3 11 30.6 2 11 2 2 2 11 3 2 2 11 3 2 2 11 3 2 2 11 3 2 2 11 3 2 2 1 3 1 3 1 3 3 1 3 3 1 3 3 1 3 3 1 3 3 1 3 3 1 3 3 1 3 3 1 3 3 1 3 3 1 3 3 1 3 3 1 3 1 3 1 3 3 1 3 3 1 3 3 1 3 1 3 3 1 3 3 1 3 1 3 1 3 1 3 1 1 3 1 3 1 3 1 3 1 3 1 3 1 3 1 3 1 3 1 1 3 1 1 3 1 1 3 1 1 1 3 1 1 3 1 1 3 1 1 1 3 1 1 1 1 1 1 1 1 1 1 1 1 1	4: .002);   <sup>2</sup> = berimenta <u>SD To</u> 14.2 : 31.9 24.3 25.2 23.3 23.3 22.3 23.3 22.3 : ;   <sup>2</sup> = 0% 22.4 28.1 32.5 : 16.1 16 23.8 23.8 23.5 25.5 2.7 :	e 469 l otal 27 9 16 10 12 21 15 20 9 3 12 10 10 10 21 15 20 9 13 12 12 10 10 12 12 10 10 12 12 10 10 10 10 10 10 10 10 10 10	( Mean 2.2 12 5.2 5.2 10.6 19 5 5.2.1 3.5 3.2 8.2 3.1 5 -4 2 2 2 7 0.3	SD 15.8 32.6 26.6 27.2 32.2 10.6 27.5 22.1 3.1 18 28.6 21.4 19 21 20.9 21.9 0.5	Total V 28 7 17 10 9 8 18 16 113 9 12 21 9 15 10 10 10 12 20	Veight, % 45.3 9.5 5.4 4.4 12.5 11.3 8.8 100 4.9 3.7 3.7 3.7 3.7 3.4 3.4 3.3 11.0	Mean Difference IV, Random, 95% Cl 15.40 (7.47 to 23.33) -7.00 (-38.90 to 24.90) 12.80 (-4.57 to 30.17) 16.20 (-6.78 to 39.18) 13.00 (-12.52 to 38.52) 6.00 (-9.09 to 21.09) 7.51 (-8.38 to 23.40) 1.80 (-16.24 to 19.84) 11.20 (5.86 to 16.54) 9.00 (-5.77 to 23.77) 17.20 (-1.16 to 35.56) 26.70 (8.18 to 45.22) 16.30 (-1.59 to 34.19) 15.00 (1.79 to 28.21) 28.60 (8.93 to 48.27) 28.60 (8.97 to 48.23) 5.00 (-15.08 to 25.08) 13.50 (12.30 to 14.70)	Favors control Favors IMT Mean Difference IV, Random, 95% Cl
df = 35 (P = . Exp Mean 17.6 5 18 2 26.8 32 11 2 5.3 5.3 2 5.3 5.3 5.3 5.3 5.3 5.3 5.3 5.3	4: .002);   <sup>2</sup> = berimenta <u>SD To</u> 14.2 : 31.9 24.3 23.3 23.3 23.3 23.3 23.3 23.3 23.3	e 469 li bital 27 9 16 10 12 21 10 10 12 13 12 10 10 20 21	C           Mean           2.2           12           2.2           10.6           19           5           2.1           3.5           3.2           8.2           3.1           5           -4           2           7           0.3           2.1           0.3           2.1	SD 15.8 32.6 26.6 27.2 32.2 10.6 27.5 22.1 18 28.6 27.5 22.1 18 28.6 21.4 19 21.4 19 21.9 0.5 27.5	Total V 28 7 17 10 9 8 18 16 113 9 12 21 9 15 10 10 10 20 18	Veight, % 45.3 2.8 9.5 5.4 4.4 12.5 11.3 8.8 100 4.9 3.7 3.7 3.7 3.7 3.7 3.7 3.8 5.5 3.4 3.4 3.4 3.3 11.0 4.5	Mean Difference IV, Random, 95% Cl 15.40 (7.47 to 23.33) -7.00 (-38.90 to 24.90) 12.80 (-4.57 to 30.17) 16.20 (-6.78 to 39.18) 13.00 (-12.52 to 38.52) 6.00 (-9.09 to 21.09) 7.51 (-8.38 to 23.40) 1.80 (-16.24 to 19.84) 11.20 (5.86 to 16.54) 9.00 (-5.77 to 23.77) 17.20 (-1.16 to 35.56) 26.70 (8.18 to 45.22) 16.30 (-1.59 to 34.19) 15.00 (1.79 to 28.21) 28.60 (8.97 to 48.23) 5.00 (-15.08 to 25.08) 13.50 (12.30 to 14.70) 7.51 (-8.38 to 23.40)	Favors control Favors IMT Mean Difference IV, Random, 95% Cl
df = 35 (P = . Exp Mean 17.6 5 3 26.8 2 26.8 2 32 2 11 2 9.61 2 2 2 5.3 2 2 2 4 2 2 2 4 2 2 2 4 3 2 2 2 3 2 2 2 3 2 2 3 2 2 3 2 2 3 2 2 3 2 2 3 2 2 3 2 2 3 2 2 3 2 2 3 2 2 3 2 2 3 2 2 3 2 2 3 2 2 3 2 2 3 2 2 3 2 2 3 2 3 2 2 3 2 2 3 2 2 3 2 2 3 2 2 3 2 2 3 2 2 3 2 2 3 2 2 3 2 2 3 2 2 3 2 2 3 2 2 3 2 2 5.3 2 2 2 5.3 2 2 2 5.3 2 2 2 5.3 2 2 2 5.3 2 2 2 5.4 3 2 2 2 5.3 2 2 2 5.4 3 2 2 2 3 3 3 11 3 3 3 6 2 2 2 3 3 3 3 6 2 2 2 3 3 3 3 6 2 2 3 3 3 3 6 2 2 3 3 3 6 2 2 3 3 3 6 2 2 3 3 3 6 2 2 3 3 3 6 2 2 3 3 3 6 2 2 7 7 7 7 7 7 7 7 7 7 7 7 7	4: .002);   <sup>2</sup> = Derimenta <u>SD To</u> 14.2 : 31.9 24.3 25.2 23.3 22.3 : 23.3 22.3 : 23.3 22.3 : 10.1 16.1 16.2 23.8 25.5 : 16.1 16.2 23.8 25.5 : 2.7 : 22.3 : 22.3 : 23.8 25.5 : 27.1 22.3 : 27.1 22.3 : 27.1 22.3 : 27.1 22.3 : 27.1 22.3 : 27.1 22.3 : 27.1 22.3 : 27.1 22.3 : 27.1 23.8 25.2 : 27.1 23.8 25.5 : 27.1 23.8 23.8 25.5 : 27.1 23.8 23.8 23.8 25.5 : 27.1 23.8 23.8 23.8 23.8 23.8 23.8 23.8 23.8	e 469 li bital 27 9 16 10 12 21 5 20 9 13 12 1 8 12 10 10 10 22 11 0 10 20 21 10	Mean           2.2           12           5.2           10.6           19           5           2.1           3.5           3.2           8.2           3.1           5           -4           2           7           0.3           2.1           -0.34	SD 15.8 32.6 26.6 27.2 32.2 22.1 3.1 18 28.6 21.4 19 21 20.9 21.9 0.5 27.5 10.9	Total V 28 7 17 10 9 8 18 16 113 9 12 21 9 15 10 10 12 20 18 10	Veight, % 45.3 2.8 9.5 5.4 4.4 12.5 11.3 8.8 100 4.9 3.7 3.7 3.8 5.5 3.4 3.4 3.3 11.0 4.5 8.6	Mean Difference IV, Random, 95% CI 15.40 (7.47 to 23.33) -7.00 (-38.90 to 24.90) 12.80 (-4.57 to 30.17) 16.20 (-6.78 to 39.18) 13.00 (-12.52 to 38.52) 6.00 (-9.09 to 21.09) 7.51 (-8.38 to 23.40) 1.80 (-16.24 to 19.84) 11.20 (5.86 to 16.54) 9.00 (-5.77 to 23.77) 17.20 (-1.16 to 35.56) 26.70 (8.18 to 45.22) 16.30 (-1.59 to 34.19) 15.00 (1.79 to 28.21) 28.60 (8.93 to 48.27) 28.60 (8.93 to 48.23) 5.00 (-15.08 to 25.08) 13.50 (12.30 to 14.70) 7.51 (-8.38 to 23.40) 3.04 (-3.92 to 10.00)	Favors control Favors IMT Mean Difference IV, Random, 95% Cl
df = 35 (P = . Exp Mean 17.6 5 3 26.8 2 26.8 2 32 2 11 2 9.61 2 2 2 5.3 2 2 2 4 2 2 2 4 2 2 2 4 3 2 2 2 3 2 2 2 3 2 2 3 2 2 3 2 2 3 2 2 3 2 2 3 2 2 3 2 2 3 2 2 3 2 2 3 2 2 3 2 2 3 2 2 3 2 2 3 2 2 3 2 2 3 2 2 3 2 2 3 2 3 2 2 3 2 2 3 2 2 3 2 2 3 2 2 3 2 2 3 2 2 3 2 2 3 2 2 3 2 2 3 2 2 3 2 2 3 2 2 3 2 2 5.3 2 2 2 5.3 2 2 2 5.3 2 2 2 5.3 2 2 2 5.3 2 2 2 5.4 3 2 2 2 5.3 2 2 2 5.4 3 2 2 2 3 3 3 11 3 3 3 6 2 2 2 3 3 3 3 6 2 2 2 3 3 3 3 6 2 2 3 3 3 3 6 2 2 3 3 3 6 2 2 3 3 3 6 2 2 3 3 3 6 2 2 3 3 3 6 2 2 3 3 3 6 2 2 7 7 7 7 7 7 7 7 7 7 7 7 7	4: .002);   <sup>2</sup> = Derimenta <u>SD To</u> 14.2 : 31.9 24.3 25.2 23.3 22.3 : 23.3 22.3 : 23.3 22.3 : 10.1 16.1 16.1 16.2 23.8 22.4 23.8 22.5 : 16.1 16.2 3.8 22.8 23.8 25.5 2.7 : 2.7 :	e 469 li bital 27 9 16 10 12 21 10 10 12 13 12 10 10 20 21	C           Mean           2.2           12           2.2           10.6           19           5           2.1           3.5           3.2           8.2           3.1           5           -4           2           7           0.3           2.1           0.3           2.1	SD 15.8 32.6 26.6 27.2 32.2 10.6 27.5 22.1 18 28.6 27.5 22.1 18 28.6 21.4 19 21.4 19 21.9 0.5 27.5	Total V 28 7 17 10 9 8 18 16 113 9 12 21 9 15 10 10 10 20 18	Veight, % 45.3 9.5 5.4 4.4 12.5 11.3 8.8 100 4.9 3.7 3.7 3.7 3.8 5.5 3.4 3.3 11.0 4.5 8.6 3.6	Mean Difference IV, Random, 95% Cl 15.40 (7.47 to 23.33) -7.00 (-38.90 to 24.90) 12.80 (-4.57 to 30.17) 16.20 (-6.78 to 39.18) 13.00 (-12.52 to 38.52) 6.00 (-9.09 to 21.09) 7.51 (-8.38 to 23.40) 1.80 (-16.24 to 19.84) 11.20 (5.86 to 16.54) 9.00 (-5.77 to 23.77) 17.20 (-1.16 to 35.56) 26.70 (8.18 to 45.22) 16.30 (-1.59 to 34.19) 15.00 (1.79 to 28.21) 28.60 (8.97 to 48.23) 5.00 (-15.08 to 25.08) 13.50 (12.30 to 14.70) 7.51 (-8.38 to 23.40)	Favors control Favors IMT Mean Difference IV, Random, 95% Cl
df = 35 (P = . Exp Mean 17.6 5 18 2 26.8 2 9.61 2 5.3 2 11 2 9.61 2 2 5.3 2 11 2 2 5.3 2 1 2 2 5.3 2 1 2 2 5.3 2 1 2 2 5.3 2 2 1 2 2 5.3 2 2 1.3 - 1 1 2 2 2 5.4 2 2 1.3 - 1 2 2 2 5.3 2 2 1.3 - 1 2 2 2 5.3 2 2 1.3 - 2 2 1.3 - 2 1.3 - 2 1.3 - 2 1.3 - 2 1.3 - 2 1.3 - 2 1.3 - 2 1.3 - 2 1.3 - 2 1.3 - 2 1.3 - 2 1.3 - 2 1.3 - 2 1.3 - 2 1.5 2 - 2 - 7 - 7 - 7 - 2 - 7 - - - - - - - - - - - - -	4: .002);   <sup>2</sup> = Derimenta SD To 14.2 : 31.9 24.3 25.2 23.3 23.3 23.3 22.3 : 23.3 23.3 23.3 23.3 23.3 23.3 23.3 23.	e 469 li bital 27 9 16 10 12 21 5 20 9 13 12 1 8 12 10 10 10 22 11 0 10 20 21 10	Mean           2.2           12           5.2           10.6           19           5           2.1           3.5           3.2           8.2           3.1           5           -4           2           7           0.3           2.1           -0.34	SD 15.8 32.6 26.6 27.2 32.2 22.1 3.1 18 28.6 21.4 19 21 20.9 21.9 0.5 27.5 10.9	Total V 28 7 17 10 9 8 18 16 113 9 12 21 9 15 10 10 12 20 18 10	Veight, % 45.3 2.8 9.5 5.4 4.4 12.5 11.3 8.8 100 4.9 3.7 3.7 3.8 5.5 3.4 3.4 3.3 11.0 4.5 8.6	Mean Difference IV, Random, 95% CI 15.40 (7.47 to 23.33) -7.00 (-38.90 to 24.90) 12.80 (-4.57 to 30.17) 16.20 (-6.78 to 39.18) 13.00 (-12.52 to 38.52) 6.00 (-9.09 to 21.09) 7.51 (-8.38 to 23.40) 1.80 (-16.24 to 19.84) 11.20 (5.86 to 16.54) 9.00 (-5.77 to 23.77) 17.20 (-1.16 to 35.56) 26.70 (8.18 to 45.22) 16.30 (-1.59 to 34.19) 15.00 (1.79 to 28.21) 28.60 (8.93 to 48.27) 28.60 (8.93 to 48.23) 5.00 (-15.08 to 25.08) 13.50 (12.30 to 14.70) 7.51 (-8.38 to 23.40) 3.04 (-3.92 to 10.00)	Favors control Favors IMT Mean Difference IV, Random, 95% Cl
df = 35 (P = . Exp Mean 17.6 18 26.8 2 11 26.8 2 11 20.6 2 12 2 5.3 2 12 2 5.3 2 11 2 2 5.4 2 2 5.4 2 2 5.4 2 2 5.4 2 2 5.4 2 2 5.4 2 2 5.4 2 2 5.4 2 2 5.4 2 2 5.4 2 2 5.4 2 2 5.4 2 2 5.4 2 2 5.3 2 1 2 2 5.4 2 2 5.4 2 2 5.4 2 2 5.3 2 2 5.3 2 2 5.3 2 2 5.3 2 2 5.3 2 2 5.3 2 2 5.3 2 2 5.3 2 2 5.3 2 2 5.3 2 2 5.4 2 2 5.4 2 2 5.4 2 2 5.4 2 2 5.4 2 2 5.3 2 1 1 3 0.6 2 2 1.3 3 1 1 3 0.6 2 2 1.3 3 1 2 2 5.3 2 1 3 3 6 2 1 3 3 6 2 1 3 3 6 2 1 3 3 5 2 1 3 3 5 2 1 3 5 2 1 3 3 5 2 1 3 3 5 2 1 3 3 5 2 1 3 5 2 1 3 5 2 1 3 5 2 1 3 5 2 1 3 5 2 1 3 5 2 1 3 5 2 1 3 5 2 1 3 5 2 1 3 5 2 5 2 5 2 5 5 5 5 5 5 5 5 5 5 5 5 5	4: .002);   <sup>2</sup> = berimenta <u>SD</u> To 14.2 31.9 24.3 25.2 23.3 22.3 22.3 22.3 22.3 22.3 22	e 469 li bital 27 9 16 10 12 21 10 12 15 20 9 13 12 1 8 12 10 10 10 20 21 10 10 10	C Mean 2.2 12 5.2 5.2 5.2 5.2 5.2 5.2 5.2 5.2 5.2 3.1 3.5 3.2 8.2 3.1 5 -4 2 7 7 0.3 2.1 -4 2 7 7 0.3 2.1 -4 2 7 2 -4 2 -2 -4 -4 -4 -4 -4 -4 -4 -4 -4 -4 -4 -4 -4	SD 15.8 32.6 26.6 27.2 32.2 10.7 5 22.1 3.1 8 28.6 21.4 19 20.9 21.9 0.5 27.5 27.5 10.9 22	Total V 28 7 17 10 9 8 18 16 113 9 12 21 9 15 10 10 12 20 18 10 10	Veight, % 45.3 9.5 5.4 4.4 12.5 11.3 8.8 100 4.9 3.7 3.7 3.7 3.8 5.5 3.4 3.3 11.0 4.5 8.6 3.6	Mean Difference IV, Random, 95% Cl 15.40 (7.47 to 23.33) -7.00 (-38.90 to 24.90) 12.80 (-4.57 to 30.17) 16.20 (-6.78 to 39.18) 13.00 (-12.52 to 38.52) 6.00 (-9.09 to 21.09) 7.51 (-8.38 to 23.40) 1.80 (-16.24 to 19.84) 11.20 (5.86 to 16.54) 9.00 (-5.77 to 23.77) 17.20 (-1.16 to 35.56) 26.70 (8.18 to 45.22) 16.30 (-1.59 to 34.19) 15.00 (1.79 to 28.21) 28.60 (8.97 to 48.23) 5.00 (-15.08 to 25.08) 13.50 (12.30 to 14.70) 7.51 (-8.38 to 23.40) 3.04 (-3.92 to 10.00) 23.40 (4.51 to 42.29)	Favors control Favors IMT Mean Difference IV, Random, 95% Cl
df = 35 (P = . Exp Mean 17.6 5 18 2 26.8 2 2 5.3 2 11 2 5.3 2 11 2 2 2 5.3 2 2 14 2 5.3 2 2 15.3 2 2 2 5.3 2 2 2 2 3 2 2 2 3 2 2 5.3 2 2 2 3 2 2 3 3 2 2 3 3 2 2 3 3 2 2 3 3 3 3 5 3 2 2 1.3 3 3 5 3 2 2 1.3 3 3 11 3 0.6 2 2 1.3 3 3 5 3 2 2 1.3 3 3 1 1 3 8 9.61 1 2 2 1.3 3 3 1 1 3 8 9.61 2 2 1.3 3 3 1 3 8 9.61 2 2 1.3 3 3 1 3 8 9.61 2 2 1.3 3 3 3 4 2 2 1.3 3 3 3 4 2 2 1.3 3 3 4 2 2 1.3 3 2 1.3 3 2 1.3 3 2 1.3 3 2 1.3 3 2 1.3 3 2 1.3 3 2 1.3 3 2 2 1.3 3 2 2 1.3 3 2 2 3 3 3 4 2 2 4 3 3 3 4 2 4 3 3 3 4 2 4 3 3 3 3 3 3 3 3 3 3 3 3 3	4: .002);   <sup>2</sup> = berimenta <u>SD</u> To 14.2 31.9 24.3 25.2 23.3 22.3 22.3 22.3 22.3 22.3 22	e 469 l otal 27 9 16 10 12 27 9 16 10 12 21 5 20 9 13 12 8 12 10 10 20 11 0 10 20 11 0 10 21 10 10 21 10 10 10 21 10 21 10 10 10 21 10 21 10 10 10	C ( Mean 2.2 12 5.2 10.6 19 5 2.1 3.5 3.2 8.2 3.1 5 4 2 2 7 0.3 2.1 3.5 3.2 3.2 3.2 3.1 5.2 3.2 3.2 3.2 3.1 5.2 3.2 3.2 3.1 5.2 3.2 3.2 3.1 5.2 3.2 3.2 3.1 5.2 3.2 3.1 5.2 3.1 5.2 3.2 3.1 5.2 3.2 3.1 5.2 3.2 3.1 5.2 3.2 3.1 5.2 3.2 3.1 5.2 3.2 3.1 5.2 3.2 3.1 3.2 3.2 3.1 5.2 3.2 3.1 5.2 3.2 3.1 5.2 3.2 3.1 5.3 3.2 3.2 3.1 5.3 3.2 3.2 3.1 5.3 3.2 3.2 3.1 5.3 3.2 3.2 3.1 5.3 3.2 3.1 5.3 3.2 3.1 5.3 3.2 3.1 5.3 3.1 5.3 3.1 5.3 3.1 5.3 5	SD 15.8 32.6 26.6 27.2 32.2 10.6 27.5 22.1 3.1 18 28.6 21.4 19 21 20.9 0.5 27.5 27.5 10.9 0.5 27.5 22.8 6	Total V 28 7 17 10 9 8 18 16 113 9 12 21 9 15 10 10 12 20 18 10 10 12	Veight, % 45.3 9.5 5.4 4.4 12.5 11.3 8.8 100 4.9 3.7 3.7 3.7 3.7 3.7 3.7 3.4 3.4 3.3 11.0 4.5 8.6 3.6 2.0	Mean Difference IV, Random, 95% Cl 15.40 (7.47 to 23.33) -7.00 (-38.90 to 24.90) 12.80 (-4.57 to 30.17) 16.20 (-6.78 to 39.18) 13.00 (-12.52 to 38.52) 6.00 (-9.09 to 21.09) 7.51 (-8.38 to 23.40) 1.80 (-16.24 to 19.84) 11.20 (5.86 to 16.54) 9.00 (-5.77 to 23.77) 17.20 (-1.16 to 35.56) 26.70 (8.18 to 45.22) 16.30 (-1.59 to 34.19) 15.00 (1.79 to 28.21) 28.60 (8.97 to 48.23) 5.00 (-15.08 to 25.08) 13.50 (12.30 to 14.70) 7.51 (-8.38 to 23.40) 3.04 (-3.92 to 10.00) 23.40 (4.51 to 42.29) 27.20 (-0.81 to 55.21)	Favors control Favors IMT Mean Difference IV, Random, 95% Cl
df = 35 (P = . Exp Mean 17.6 5 3 26.8 2 2 11 2 9.61 2 5.3 2 = 7 (P = .75); 12.2 2 25.4 2 29.8 3 21.3 2 11 30.6 2 30.6 2 12 2 13.8 9.61 2 2.7 21.6 2 30.3 2 12 2 13.8 9.61 2 2.7 21.6 2 30.6 2 12 2 13.8 9.61 2 2.7 2.16 2 3.03 2 2.7 2.16 2 3.03 2 2.7 2.16 2 3.03 2 2.7 2.16 2 3.12 2 2.7 2.16 2 3.12 2 2.7 2.16 2 3.12 2 2.7 2.16 2 3.12 2 2.7 2.16 2 3.12 2 3.12 2 2.7 2.16 2 3.12 3 3.12 2 3.12 3 3.12 3 3.1	44: .002); $ ^2 =$ berimenta SD To 14.2 : 31.9 24.3 23.5 16.1 16.2 23.8 23.8 23.8 23.8 23.8 23.8 23.8 23.8 23.8 23.8 23.8 23.8 23.8 23.8 23.8 23.7 21.1 40.4 11.9 16.4 11.9	e 469 lotal 27 9 16 10 10 27 9 16 10 10 21 10 10 21 10 10 21 10 10 21 10 10 10 10 10 10 10 10 10 10 10 10 10	Mean           2.2           12           5.2           10.6           19           5           2.1           3.5           3.2           8.2           3.1           5           -4           2           7           0.34           -1.8           3.1           24           2           2           2           2           2           3.1           24           2           3.1           24           2           3.1           24           25	SD 15.8 32.6 26.6 27.2 32.2 10.6 27.5 22.1 3.1 18 8.6 27.5 22.1 20.9 21.9 0.5 27.5 27.5 10.9 21.9 0.5 27.5 27.5 27.5 21.4 10.6 20.9 21.2 20.9 21.2 20.9 21.2 20.9 21.2 20.9 21.2 20.0 21.2 20.0 20.2 20.0 20.2 20.0 20.2 20.0 20.2 20.0 20.2 20.0 20.2 20.0 20.2 20.0 20.2 20.0 20.2 20.0 20.2 20.0 20.2 20.0 20.2 20.0 20.2 20.0	Total V 28 7 17 10 9 8 18 16 113 9 12 21 9 15 10 10 12 20 18 10 10 12 4 8	Veight, % 45.3 2.8 9.5 5.4 4.4 12.5 11.3 8.8 100 4.9 3.7 3.7 3.8 5.5 3.4 3.4 3.3 11.0 4.5 8.6 6 3.6 2.0 4 5.5	Mean Difference IV, Random, 95% CI 15.40 (7.47 to 23.33) -7.00 (-38.90 to 24.90) 12.80 (-4.57 to 30.17) 16.20 (-6.78 to 39.18) 13.00 (-12.52 to 38.52) 6.00 (-9.09 to 21.09) 7.51 (-8.38 to 23.40) 1.80 (-16.24 to 19.84) 11.20 (5.86 to 16.54) 9.00 (-5.77 to 23.77) 17.20 (-1.16 to 35.56) 26.70 (8.18 to 45.22) 16.30 (-1.59 to 34.19) 15.00 (-1.79 to 28.21) 28.60 (8.93 to 48.23) 5.00 (-15.08 to 25.08) 13.50 (12.30 to 14.70) 7.51 (-8.38 to 23.40) 3.04 (-3.92 to 10.00) 23.40 (4.51 to 52.21) -11.60 (-2.28 4 to -0.36) 10.00 (-3.11 to 23.11)	Favors control Favors IMT Mean Difference IV, Random, 95% Cl
$df = 35 (P = \\ Exp \\ Mean$ $17.6 \\ 5 \\ 18 \\ 26.8 \\ 2 \\ 11 \\ 29.61 \\ 5.3 \\ 2 \\ 11 \\ 29.61 \\ 5.3 \\ 2 \\ 11 \\ 29.61 \\ 21 \\ 30.6 \\ 21.3 \\ 11 \\ 30.6 \\ 21.3 \\ 11 \\ 30.6 \\ 2.7 \\ 21.6 \\ 2.7 \\ 2.7 \\ 21.6 \\ 2.7 \\ 2.7 \\ 21.6 \\ 2.7 \\ 2.7 \\ 2.7 \\ 2.1 \\ 2.7 \\ 2.7 \\ 2.7 \\ 2.1 \\ 2.7 \\ 2.7 \\ 2.7 \\ 2.1 \\ 2.7 \\ 2.7 \\ 2.1 \\ 2.7 \\$	4: .002); $ ^2 =$ berimenta SD To 14.2 : 31.9 24.3 25.2 23.3 23.3 22.3 : 23.3 22.3 : 28.5 1: 16.1 32.5 : 16.1 16 23.8 25.5 : 27.7 : 21.1 40.4 16.4 16.4 16.4 16.9 30.8 16.1 16.1 16.1 16.1 16.1 16.1 16.1 16	$ \begin{array}{c} = 46\% \\ \text{il} \\ 27 \\ 9 \\ 10 \\ 121 \\ 27 \\ 9 \\ 10 \\ 10 \\ 121 \\ 10 \\ 10 \\ 10 \\ 10 \\ 1$	C         Mean           2.2         12         5.2           10.6         19         5.2           11.3.5         3.2         8.2           3.1         5         -4           2         2         7         7           0.3         2.1         -1.8         3.1           -1.4         2         2         2           2.1         -1.4         2         2           2.1         -1.4         2         2           2.1         -1.4         2         2           2.1         -1.4         2         2           2.1         -1.4         2         2	SD 15.8 32.6 26.6 27.2 32.2 10.6 27.5 22.1 3.1 18 28.6 21.4 19 21 20.9 21.4 19 21.2 21.9 0.5 27.5 22.5 10.9 22.2 8.6 5.8 14.7 27.5	Total V 28 7 17 10 9 8 18 16 113 9 12 21 9 12 21 9 15 10 10 12 20 18 10 10 12 4 8 19	Veight, % 45.3 9.5 5.4 4.4 12.5 11.3 8.8 100 4.9 3.7 3.7 3.7 3.7 3.4 3.4 3.3 11.0 4.5 8.6 3.6 2.0 6.4 5.5 3.7	Mean Difference IV, Random, 95% Cl 15.40 (7.47 to 23.33) -7.00 (-38.90 to 24.90) 12.80 (-4.57 to 30.17) 16.20 (-6.78 to 39.18) 13.00 (-12.52 to 38.52) 6.00 (-9.09 to 21.09) 7.51 (-8.38 to 23.40) 1.80 (-16.24 to 19.84) 11.20 (5.86 to 16.54) 9.00 (-5.77 to 23.77) 17.20 (-1.16 to 35.56) 26.70 (8.18 to 45.22) 16.30 (-1.59 to 34.19) 15.00 (1.79 to 28.21) 28.60 (8.93 to 48.27) 28.60 (8.97 to 48.23) 5.00 (-15.08 to 25.08) 13.50 (12.30 to 14.70) 7.51 (-8.38 to 23.40) 3.04 (-3.51 to 23.24) 27.20 (-0.81 to 55.21) -11.60 (-22.84 to -0.36) 10.00 (-3.11 to 23.11) 0.00 (-18.57 to 18.57)	Favors control Favors IMT Mean Difference IV, Random, 95% Cl
df = 35 (P = . <u>Mean</u> 17.6 18 26.8 2 11 26.8 2 11 26.8 2 11 20.6 2 5.3 2 12 2 25.4 2 25.4 2 25.4 2 25.4 2 2 3 0.6 2 2 2 3 2 1 2 2 2 4 2 2 3 2 1 2 2 2 4 2 2 3 2 1 2 2 2 4 2 2 3 3 2 2 3 3 2 2 3 3 2 2 3 3 2 2 3 3 2 2 3 3 3 2 2 3 3 3 2 2 3 3 3 2 2 3 3 3 2 2 3 3 3 2 2 3 3 3 2 2 3 3 3 2 2 3 3 3 3 2 2 3 3 3 3 2 2 3 3 3 3 3 3 3 3 3 3 3 3 3	44: .002);  2 = Derimenta SD To 14.2 :: 31.9 24.3 23.3 223.3 225.2 23.3 225.2 23.3 225.2 23.3 225.2 23.3 23.3	$ \begin{array}{c} = 46\% \\ \text{l} \\ \text{total} \\ 27 \\ 9 \\ 10 \\ 10 \\ 12 \\ 15 \\ 20 \\ 9 \\ 13 \\ 10 \\ 10 \\ 21 \\ 10 \\ 21 \\ 10 \\ 12 \\ 11 \\ 11$	C         Mean           2.2         12           12         5.2           10.6         19           5         3.5           3.2         8.2           3.1         5           -4         2           2.1         -0.34           -1.8         3.1           24         2           21         1.5	SD 15.8 32.6 26.6 27.2 32.2 32.2 10.6 27.5 22.1 8 8 8.6 21.4 19 21 20.9 0.5 27.5 27.5 10.9 0.5 27.5 28.6 5.8 14.7 5.8	Total V 28 7 17 10 9 8 18 16 113 9 12 21 9 15 10 10 12 20 18 10 10 12 20 18 10 10 21 21 12 21 10 12 21 10 12 21 10 12 21 20 12 21 20 12 21 20 20 20 20 20 20 20 20 20 20 20 20 20	Veight, % 45.3 2.8 9.5 5.4 4.4 12.5 11.3 8.8 100 4.9 3.7 3.7 3.7 3.7 3.7 3.7 3.7 3.7 3.4 3.4 3.4 3.4 3.4 3.10 11.0 4.5 8.6 6 3.6 6 2.0 6.4 5.7 7 6.4	Mean Difference IV, Random, 95% Cl 15.40 (7.47 to 23.33) -7.00 (-38.90 to 24.90) 12.80 (-4.57 to 30.17) 16.20 (-6.78 to 39.18) 13.00 (-12.52 to 38.52) 6.00 (-9.09 to 21.09) 7.51 (-8.38 to 23.40) 1.80 (-16.24 to 19.84) 11.20 (5.86 to 16.54) 9.00 (-5.77 to 23.77) 17.20 (-1.16 to 35.56) 26.70 (8.18 to 45.22) 16.30 (-1.59 to 34.19) 15.00 (1.79 to 28.21) 28.60 (8.97 to 48.23) 5.00 (-15.08 to 25.08) 13.50 (12.30 to 14.70) 7.51 (-8.38 to 23.40) 3.04 (-3.92 to 10.00) 23.40 (4.51 to 42.29) 27.20 (-0.81 to 55.21) -11.60 (-22.84 to -0.36) 10.00 (-3.11 to 23.11) 0.00 (-18.57 to 18.57) 17.80 (6.68 to 28.92)	Favors control Favors IMT Mean Difference IV, Random, 95% Cl
df = 35 (P = . Exp Mean 17.6 5 18 2 26.8 2 32 11 2 5.3 2 11 2 5.3 2 2 11 2 5.3 2 2 11 2 5.3 2 2 11 2 5.3 2 2 11 2 5.3 2 2 11 2 5.3 2 2 11 2 5.3 2 2 11 2 5.3 2 2 15 3 2 2 15 3 2 2 15 3 2 2 15 3 2 2 15 3 2 2 15 3 2 2 15 3 2 2 15 3 2 2 15 3 2 2 2 15 3 2 2 2 15 3 2 2 2 15 3 2 2 2 15 3 2 2 2 15 3 2 2 2 15 3 2 2 15 3 2 2 2 15 3 2 2 15 3 2 2 15 3 2 2 13 3 3 0.6 2 2 13 3 3 0.6 2 2 13 3 3 0.6 2 2 13 3 3 3 16 2 2 13 3 3 3 2 12 2 13 3 2 13 3 3 2 12 2 13 2 13 2 13 2 13 2 12 2 13 2 13 2 12 2 13 2 12 2 13 2 13 2 12 2 13 2 12 2 13 2 12 2 12 2 13 2 12 2 13 2 12 2 12 2 13 2 12 2 1 2 12 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 2 1 2 2 1 2 1 2 2 1 2 1 2 2 1 2 2 1 2 1 2 2 2 1 2 2 2 1 2 2 1 2 1 2 2 1 2 2 1 2 1 2 1 2 1 2 2 1 2 1 2 2 1 2 1 2 1 2 2 1 2 2 1 2 1 2 2 1 2 2 1 2 1 2 2 2 1 2 2 1 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2	44: .002); $ ^2 =$ Derimenta SD To 14.2 : 31.9 24.3 25.2 23.3 22.3 : 28.5 10: 16.1 16.2 22.4 22.4 22.4 22.4 23.8 23.7 21.1 10.4 10.4 11.9 30.8 11.7 13.1	a 46% line 127 96100 913120 913120 913120 913120 1121120 913120 11211120 1121120 112111200 112111200000000	Mean           2.2           12.2           12.2           12.2           10.6           19           5           2.1           -0.34           -1.8           3.1           -1.8           3.1           -2           2           1.034           -0.34           -0.34           0.8	SD 15.8 32.6 26.6 27.2 32.2 10.6 27.5 22.1 3.1 18 28.6 21.4 20.9 21.9 0.5 27.5 10.9 22.2 27.5 10.9 22.8 6.5.8 14.7 27.5 5.8 9.9	Total V 28 7 17 10 9 8 18 16 113 9 12 21 9 15 10 10 12 20 18 10 10 12 20 18 10 10 12 21 9 15 10 10 12 21 9 15 10 10 12 21 10 10 12 21 10 10 12 21 10 10 12 21 10 10 12 21 10 10 12 21 10 10 12 10 10 10 12 11 10 10 10 10 10 10 10 10 10 10 10 10	Veight, % 45.3 2.8 9.5 5.4 4.4 12.5 11.3 8.8 100 4.9 3.7 3.7 3.8 5.5 3.4 3.3 11.0 4.5 5.3,4 3.3 11.0 4.5 5.3,4 3.4 3.3 11.0 4.5 5.3,7 4.3,7 5.5 5.4 4.9 5.5 5.4 5.5 5.4 5.5 5.4 5.5 5.4 5.5 5.5	Mean Difference IV, Random, 95% CI 15.40 (7.47 to 23.33) -7.00 (-38.90 to 24.90) 12.80 (-4.57 to 30.17) 16.20 (-6.78 to 39.18) 13.00 (-12.52 to 38.52) 6.00 (-9.09 to 21.09) 7.51 (-8.38 to 23.40) 1.80 (-16.24 to 19.84) 11.20 (5.86 to 16.54) 9.00 (-5.77 to 23.77) 17.20 (-1.16 to 35.56) 26.70 (.8.18 to 45.22) 16.30 (-1.59 to 34.19) 15.00 (1.79 to 28.21) 28.60 (8.93 to 48.27) 28.60 (8.93 to 48.23) 5.00 (-15.08 to 25.08) 13.50 (12.30 to 14.70) 7.51 (-8.38 to 23.40) 3.04 (-3.92 to 10.00) 23.40 (4.51 to 42.29) 27.20 (-0.81 to 55.21) -11.60 (-22.84 to -0.36) 10.00 (-3.11 to 23.11) 0.00 (-18.57 to 18.57) 17.80 (6.68 to 28.92) 11.60 (3.00 to 20.20)	Favors control Favors IMT Mean Difference IV, Random, 95% Cl
df = 35 (P = . Exp Mean 17.6 5 18 2 26.8 2 32 11 2 5.3 2 11 2 5.3 2 2 11 2 5.3 2 2 11 2 5.3 2 2 11 2 5.3 2 2 11 2 5.3 2 2 11 2 5.3 2 2 11 2 5.3 2 2 11 2 5.3 2 2 15 3 2 2 15 3 2 2 15 3 2 2 15 3 2 2 15 3 2 2 15 3 2 2 15 3 2 2 15 3 2 2 15 3 2 2 2 15 3 2 2 2 15 3 2 2 2 15 3 2 2 2 15 3 2 2 2 15 3 2 2 2 15 3 2 2 15 3 2 2 2 15 3 2 2 15 3 2 2 15 3 2 2 13 3 3 0.6 2 2 13 3 3 0.6 2 2 13 3 3 0.6 2 2 13 3 3 3 16 2 2 13 3 3 3 2 12 2 13 3 2 13 3 3 2 12 2 13 2 13 2 13 2 13 2 12 2 13 2 13 2 12 2 13 2 12 2 13 2 13 2 12 2 13 2 12 2 13 2 12 2 12 2 13 2 12 2 13 2 12 2 12 2 13 2 12 2 1 2 12 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 2 1 2 2 1 2 1 2 2 1 2 1 2 2 1 2 2 1 2 1 2 2 2 1 2 2 2 1 2 2 1 2 1 2 2 1 2 2 1 2 1 2 1 2 1 2 2 1 2 1 2 2 1 2 1 2 1 2 2 1 2 2 1 2 1 2 2 1 2 2 1 2 1 2 2 2 1 2 2 1 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2	4: .002);   <sup>2</sup> = berimenta <u>SD To</u> 14.2 : 31.9 24.3 25.2 23.3 23.3 22.3 : 23.3 22.3 : 23.3 22.3 : 23.5 : 16.1 16 23.8 25.5 : 16.1 16 23.8 25.5 : 27.7 : 21.1 40.4 11.9 30.8 11.7 13.1 8.5	a 46% in the second sec	Mean           2.2           12.2           12.2           12.2           10.6           19           5           2.1           -0.34           -1.8           3.1           -1.8           3.1           -2           2           1.034           -0.34           -0.34           0.8	SD 15.8 32.6 26.6 27.2 32.2 32.2 10.6 27.5 22.1 8 8 8.6 21.4 19 21 20.9 0.5 27.5 27.5 10.9 0.5 27.5 28.6 5.8 14.7 5.8	Total V 28 7 17 10 9 8 18 16 113 9 12 21 9 15 10 10 12 20 18 10 10 12 20 18 10 12 20 18 10 12 21 9 15 10 10 12 20 17 17 10 9 12 21 9 15 10 10 12 21 10 12 20 12 10 12 12 21 10 12 20 12 12 20 12 21 10 12 20 10 10 12 20 10 12 20 10 12 20 10 12 20 10 10 10 10 10 10 10 10 10 10 10 10 10	Veight, % 45.3 2.8 9.5 5.4 4.4 12.5 11.3 8.8 100 4.9 3.7 3.7 3.8 5.5 3.4 4.3 3.1 1.0 4.5 8.6 2.0 6.4 5.3.7 6.4 7.7 9.1	Mean Difference IV, Random, 95% Cl 15.40 (7.47 to 23.33) -7.00 (-38.90 to 24.90) 12.80 (-4.57 to 30.17) 16.20 (-6.78 to 39.18) 13.00 (-12.52 to 38.52) 6.00 (-9.09 to 21.09) 7.51 (-8.38 to 23.40) 1.80 (-16.24 to 19.84) 11.20 (5.86 to 16.54) 9.00 (-5.77 to 23.77) 17.20 (-1.16 to 35.56) 26.70 (8.18 to 45.22) 16.30 (-1.59 to 34.19) 15.00 (1.79 to 28.21) 28.60 (8.97 to 48.23) 5.00 (-15.08 to 25.08) 13.50 (12.30 to 14.70) 7.51 (-8.38 to 23.40) 3.04 (-3.92 to 10.00) 23.40 (4.51 to 42.29) 27.20 (-0.81 to 55.21) -11.60 (-22.84 to -0.36) 10.00 (-18.57 to 18.57) 17.80 (6.68 to 28.92) 11.60 (300 to 20.20) 0.90 (-5.10 to 6.90)	Favors control Favors IMT Mean Difference IV, Random, 95% Cl
df = 35 (P = . Exp Mean 17.6 5 18 2 26.8 2 32 11 2 5.3 2 11 2 5.3 2 2 11 2 5.3 2 2 11 2 5.3 2 2 11 2 5.3 2 2 11 2 5.3 2 2 11 2 5.3 2 2 11 2 5.3 2 2 11 2 5.3 2 2 15 3 2 2 15 3 2 2 15 3 2 2 15 3 2 2 15 3 2 2 15 3 2 2 15 3 2 2 15 3 2 2 15 3 2 2 2 15 3 2 2 2 15 3 2 2 2 15 3 2 2 2 15 3 2 2 2 15 3 2 2 2 15 3 2 2 15 3 2 2 2 15 3 2 2 15 3 2 2 15 3 2 2 13 3 3 0.6 2 2 13 3 3 0.6 2 2 13 3 3 0.6 2 2 13 3 3 3 16 2 2 13 3 3 3 2 12 2 13 3 2 13 3 3 2 12 2 13 2 13 2 13 2 13 2 12 2 13 2 13 2 12 2 13 2 12 2 13 2 13 2 12 2 13 2 12 2 13 2 12 2 12 2 13 2 12 2 13 2 12 2 12 2 13 2 12 2 1 2 12 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 2 1 2 2 1 2 1 2 2 1 2 1 2 2 1 2 2 1 2 1 2 2 2 1 2 2 2 1 2 2 1 2 1 2 2 1 2 2 1 2 1 2 1 2 1 2 2 1 2 1 2 2 1 2 1 2 1 2 2 1 2 2 1 2 1 2 2 1 2 2 1 2 1 2 2 2 1 2 2 1 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2	44: .002); $ ^2 =$ berimenta SD To 14.2 : 31.9 24.3 25.2 23.3 23.3 23.3 23.3 23.3 22.3 : 10.1 16.1 16.2 23.8 22.4 23.5 : 10.1 16.2 23.8 25.5 : 2.7 21.1 40.4 16.4 16.4 11.9 30.8 11.7 13.1 8.5 2.2 2.4 2.5 2.7 2.7 2.7 2.7 2.7 2.7 2.7 2.7	a 46% l otal 27 9 16 10 12 12 27 9 16 10 12 12 10 21 10 22 10 21 10 22 10 21 10 22 10 21 10 22 10 21 10 22 10 21 10 22 10 2	C         Mean           2.2         12           12         5.2           10.6         19           5         5.1           3.5         3.5           3.2         8.2           3.1         5           5.2         2           0.3         2.1           -0.34         2.1           -1.8         3.1           2.4         2           2.1         1.5           0.8         7.6	SD 15.8 32.6 26.6 27.2 32.2 10.6 27.5 22.1 3.1 18 28.6 21.4 20.9 21.9 0.5 27.5 10.9 22.2 27.5 10.9 22.8 6.5.8 14.7 27.5 5.8 9.9	Total V 28 7 17 10 9 8 18 16 113 9 12 21 9 15 10 10 12 20 18 10 10 12 20 18 10 10 12 21 9 15 10 10 12 21 9 15 10 10 12 21 10 10 12 21 10 10 12 21 10 10 12 21 10 10 12 21 10 10 12 21 10 10 12 10 10 10 12 11 10 10 10 10 10 10 10 10 10 10 10 10	Veight, % 45.3 2.8 9.5 5.4 4.4 12.5 11.3 8.8 100 4.9 3.7 3.7 3.8 5.5 3.4 3.3 11.0 4.5 5.3,4 3.3 11.0 4.5 5.3,4 3.4 3.3 11.0 4.5 5.3,7 4.3,7 5.5 5.4 4.9 5.5 5.4 5.5 5.4 5.5 5.4 5.5 5.4 5.5 5.5	Mean Difference IV, Random, 95% CI 15.40 (7.47 to 23.33) -7.00 (-38.90 to 24.90) 12.80 (-4.57 to 30.17) 16.20 (-6.78 to 39.18) 13.00 (-12.52 to 38.52) 6.00 (-9.09 to 21.09) 7.51 (-8.38 to 23.40) 1.80 (-16.24 to 19.84) 11.20 (5.86 to 16.54) 9.00 (-5.77 to 23.77) 17.20 (-1.16 to 35.56) 26.70 (.8.18 to 45.22) 16.30 (-1.59 to 34.19) 15.00 (1.79 to 28.21) 28.60 (8.93 to 48.27) 28.60 (8.93 to 48.23) 5.00 (-15.08 to 25.08) 13.50 (12.30 to 14.70) 7.51 (-8.38 to 23.40) 3.04 (-3.92 to 10.00) 23.40 (4.51 to 42.29) 27.20 (-0.81 to 55.21) -11.60 (-22.84 to -0.36) 10.00 (-3.11 to 23.11) 0.00 (-18.57 to 18.57) 17.80 (6.68 to 28.92) 11.60 (3.00 to 20.20)	Favors control Favors IMT Mean Difference IV, Random, 95% Cl
	$\begin{array}{c} 25.4\\ 29.8\\ 21.3\\ 18\\ 17.6\\ 51\\ 14\\ 4\\ 11\\ 30.6\\ 30.6\\ 18\\ 26.8\\ 7\\ 32\\ 12\\ 30\\ 23.7\\ 13.8\\ 13\\ 9.61\\ 2.7\\ 11\\ 10\\ 22\\ 21.6\\ 5.3\\ 25.2\\ 30.3\\ 12.4\\ 12\\ 21.6\\ 5.3\\ 25.2\\ 30.3\\ 12.4\\ 12\\ 21\\ 19.3\\ 12.4\\ \end{array}$	$\begin{array}{ccccc} 25.4 & 28.1 \\ 29.8 & 32.5 \\ 21.3 & 16.1 \\ 18 & 28.7 \\ 17.6 & 14.2 \\ 5 & 31.9 \\ 11 & 16 \\ 4 & 33.9 \\ 11 & 42 \\ 30.6 & 23.8 \\ 30.6 & 23.8 \\ 30.6 & 23.8 \\ 18 & 24.3 \\ 26.8 & 25.2 \\ 7 & 40.3 \\ 22.3 \\ 31 & 22.5 \\ 30 & 27.9 \\ 23.7 & 23.6 \\ 12 & 25.5 \\ 30 & 27.9 \\ 23.7 & 23.6 \\ 12 & 25.5 \\ 30 & 27.9 \\ 23.7 & 23.6 \\ 13.8 & 2.7 \\ 13 & 30.6 \\ 9.61 & 22.3 \\ 2.7 & 2.7 \\ 11 & 23.3 \\ 10 & 13.7 \\ 22 & 31.1 \\ 21.6 & 21.1 \\ 5.3 & 28.5 \\ 25.2 & 15.8 \\ 30.3 & 40.4 \\ 12.4 & 16.4 \\ 12 & 11.9 \\ 21 & 30.8 \\ 19.3 & 11.7 \\ 12.4 & 13.1 \\ \end{array}$	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	$\begin{array}{cccccccccccccccccccccccccccccccccccc$

Fig. 2. A: P<sub>Imax</sub> for treatment with isolated IMT against control group. P<sub>Imax</sub> = maximum inspiratory pressure; IMT = inspiratory muscle training.

# Respiratory Care $\bullet \bullet \bullet$ Vol $\bullet \bullet No \bullet$

#### Table 1. Quality of Evidence

Measure of Result	Studies, no.	Risk of Bias	Inconsistency	Indirect Evidence	Imprecision	Absolute Difference (95% CI)	Quality of Evidence
Isolated IMT							
P <sub>Imax</sub>	36	Serious*	Serious <sup>†</sup>	Not serious	Not serious	10.94 (7.98 to 13.89)	Low
FVC	10	Serious*	Very serious <sup>‡</sup>	Not serious	Serious <sup>§</sup>	-0.28 (-0.62 to 0.07)	Very low
$FEV_1$	10	Serious*	Not serious	Not serious	Not serious	0.08 (0.02 to 0.13)	Moderate
Vital capacity	3	Serious*	Not serious	Not serious	Serious <sup>§</sup>	-0.08 (-0.81  to  0.64)	Low
6-min walk test	22	Serious*	Not serious	Not serious	Serious <sup>§</sup>	34.28 (29.43 to 39.14)	Low
$\dot{V}_{O_2}$	3	Serious*	Serious <sup>†</sup>	Not serious	Serious <sup>§</sup>	0.12 (-0.14 to 0.39)	Very low
Dyspnea	12	Not serious	Very serious <sup>‡</sup>	Not serious	Serious <sup>§</sup>	-0.37 (-1.21 to 0.47)	Very low
Quality of life	2	Serious*	Not serious	Not serious	Very serious§	18.85 (-8.00 to 45.70)	Very low
Associated IMT							
P <sub>Imax</sub>	8	Serious*	Not serious	Not serious	Not serious	8.44 (4.98 to 11.91)	Moderate
6-min walk test	5	Not serious	Serious <sup>†</sup>	Not serious	Not serious	3.13 (-13.7 to 19.95)	Moderate
$\dot{V}_{O_2}$	3	Serious*	Not serious	Not serious	Serious <sup>§</sup>	-0.02 (-0.22 to 0.19)	Low

\* Limitations on methodology.

† Moderate heterogeneity.

‡ High heterogeneity.

§ Large CI.

IMT = inspiratory muscle training

PImax = maximum inspiratory pressure

P<sub>Emax</sub> = maximum expiratory pressure

 $\dot{\mathrm{V}}_{\mathrm{O}_2} =$  maximum oxygen consumption

	Exp	erimer	ntal	C	Control			Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight, %	IV, Random, 95% CI	IV, Random, 95% CI
) Imax									
Beaumont et al	14.8	26.3	74	9.9	26.8	75	16.5	4.90 (-3.63 to 13.43)	
Beaumont et al	5.6	31.8	16	3	40.4	18	2.0	2.60 (-21.71 to 26.91)	
Dekhuijzen et al	26.5	37.6	20	20.3	29.1	20	2.8	6.20 (-14.64 to 27.04)	
Dellweg et al	20	13.6	15	8	16.4	14	9.9	12.00 (0.99 to 23.01)	
Larson et al	15	27.2	14	9	36	13	2.0	6.00 (-18.21 to 30.21)	
Mador et al	10.9	46	15	5.1	33.5	14	1.4	5.80 (-23.35 to 34.95)	
Schultz et al	18.7	29.2	300	9	26.8	302	59.9	9.70 (5.22 to 14.18)	I - <b>-</b>
Wang et al	5.2	32.4	28	1.4	23.1	27	5.5	3.80 (-11.03 to 18.631	
Subtotal (95% CI)			482			483	100	8.44 (4.98 to 11.91)	
leterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 2.08, df =	7 ( <i>P</i> = .96);	l <sup>2</sup> = 0 <sup>6</sup>	%					,	
est for overall effect: $Z = 4.78 (P < .001)$									
Vith weakness									
Dekhuijzen et al	26.5	37.6	20	20.3	29.1	20	14.1	6.20 (-14.64 to 27.04)	
Dellweg et al	20	13.6	15	8	16.4	14	50.7	12.00 (0.99 to 23.01)	
Mador et al	10.9	46	15	5.1	33.5	14	7.2	5.80 (-23.35 to 34.95)	
Wang et al	5.2	32.4	28	1.4	23.1	27	27.9	3.80 (-11.03 to 18.63)	
Subtotal (95% CI)			78			75	100	8.44 (0.60 to 16.28)	
leterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 0.85, df =	3 (P = .84);	$l^2 = 0$	%						
est for overall effect: $Z = 2.11 (P = .03)$	( ),								
Vithout weakness									
Beaumont et al	14.8	26.3	74	9.9	26.8	75	20.7	4.90 (-3.63 to 13.43)	
Beaumont et al	5.6	31.8	16	3	40.4	18	2.5	2.60 (-21.71 to 26.91)	
Mador et al	10.9	46	15	5.1	33.5	14	1.8	5.80 (-23.35 to 34.95)	
Schultz et al	18.7	29.2	300	9	26.8	302	75.0	9.70 (5.22 to 14.18)	
Subtotal (95% CI)			405	0	20.0	409	100	8.46 (4.58 to 12.34)	
Heterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 1.22, df =	3(P = 75)	$l^2 = 0^{0}$				.50	100	0.10 (1.00 10 12.04)	<b>▼</b>
est for overall effect: $Z = 4.27$ ( $P < .001$ )	o (, o),								-20 -10 0 10 20
									Favors control Favors IMT

Fig. 3. P<sub>Imax</sub> for treatment with associated IMT against control group. P<sub>Imax</sub> = maximum inspiratory pressure; IMT = inspiratory muscle training.

subjects). The comparison between IMT and control groups revealed an improvement in  $FEV_1$  (0.08, 95% CI 0.02– 0.13, I<sup>2</sup>: 0%) (Fig. 4). Based on the GRADE approach, the quality of evidence for this result was moderate due to methodology limitations and inconsistency of results (Table 1). For the 6 studies that only included subjects with inspiratory muscle weakness,<sup>18,19,24,26,32,52</sup> there was no significant difference (-0.02, 95% CI -0.17 to 0.13, I<sup>2</sup>: 0%). However, in the analysis of subjects without muscle weakness, there was improvement of this outcome (0.09, 95%)

Study or Subgroup	Ex Mean	perimei SD	ntal Total	( Mean	Control SD	Total	Weight, %	Mean Difference IV, Random, 95% Cl	Mean Difference IV, Random, 95% CI
EV1									
Basso-Vanelli et al	0	0.36	13	0	0.36	12	3.9	0.00 (-0.28 to 0.28)	
Belman et al	0.02	0.57	8	0.02	0.57	9	1.1	0.00 (-0.54 to 0.54)	
Cooper et al	0.1	0.4	9	0.1	0.6	7	1.2	0.00 (-0.52 to 0.52)	
Harver et al	0	0.4	10	0	0.4	9	2.4	0.00 (-0.36 to 0.36)	
Hill et al	-0.1	0.64	16	-0.1	0.64	17	1.6	0.00 (-0.44 to 0.44)	
Koppers et al	0.1	0.7	18	0.1	0.7	18	1.5	0.00 (-0.46 to 0.46)	
Leelarungrayub et al	-0.04	0.55	10	-0.04	0.55	10	1.3	0.00 (-0.48 to 0.48)	
Mehani SHM	0.1	0.1	20	0	0.1	20	81.6	0.10 (0.04 to 0.16)	
Sudo et al	0	0.4	7	0	0.4	6	1.6	0.00 (-0.44 to 0.44)	
Wu et al	-0.07	0.3	19	0	0.6	21	3.7	-0.07 (-0.36 to 0.22)	
Subtotal (95% CI)			130			129	100	0.08 (0.02 to 0.13)	<b>▲</b>
Heterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 2.58, Test for overall effect: $Z = 2.76$ ( $P = .006$		8); I <sup>2</sup> = C	)%						
With weakness									
Basso-Vanelli et al	0	0.36	13	0	0.36	12	27.8	0.00 (-0.28 to 0.28)	<b>+</b>
Belman et al	0.02	0.57	8	0.02		9	7.5	0.00 (-0.54 to 0.54)	
Harver et al	0	0.4	10	0	0.4	9	17.1	0.00 (-0.36 to 0.36)	
Hill et al	-0.1	0.64	16	-0.1	0.64	17	11.6	0.00 (-0.44 to 0.44)	
Leelarungrayub et al	-0.04	0.55	10	-0.04	0.55	10	9.5	0.00 (-0.48 to 0.48)	
Wu et al	-0.07	0.3	19	0	0.6	21	26.4	-0.07 (-0.36 to 0.22)	
Subtotal (95% CI)			76			78	100	-0.02 (-0.17 to 0.13)	
Heterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 0.16, Test for overall effect: Z = 0.24 ( $P$ = .81)	df = 5 ( <i>P</i> > .99	9); I <sup>2</sup> = C	1%						
Without weakness									
Cooper et al	0.1	0.4	9	0.1	0.6	7	1.4	0.00 (-0.52 to 0.52)	
Koppers et al	0.1	0.7	18	0.1	0.7	18	1.7	0.00 (-0.46 to 0.46)	
Mehani SHM	0.1	0.1	20	0	0.1	20	95.0	0.10 (0.04 to 0.16)	-
Sudo et al	0	0.4	7	0	0.4	6	1.9	0.00 (-0.44 to 0.44)	
Subtotal (95% CI)			54			51	100	0.09 (0.03 to 0.16)	<b> </b> ◆
Heterogeneity: $Tau^2 = 0.00$ ; $Chi^2 = 0.50$ , Test for overall effect: Z = 3.08 ( <i>P</i> = .002		6); I <sup>2</sup> = C	)%						
Load to 35%	0	0.4	10	0	0.4	9	59.5	0.00 (-0.36 to 0.36)	
Harver et al Sudo et al	0	0.4 0.4	10 7	0	0.4 0.4	9	59.5 40.5	0.00 (-0.36 to 0.36) 0.00 (-0.44 to 0.44)	
	0	0.4	17	0	0.4	ь 15	40.5 100	( )	
Subtotal (95% Cl) Heterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 0.00, Test for overall effect: Z = 0.00 ( $P$ = 1.00		9); I <sup>2</sup> = C				15	100	0.00 (-0.28 to 0.28)	
6-8 Weeks									
Belman et al	0.02		8	0.02		9	1.1	0.00 (-0.54 to 0.54)	
Cooper et al	0.1	0.4	9	0.1	0.6	7	1.3	0.00 (-0.52 to 0.52)	
Harver et al	0	0.4	10	0	0.4	9	2.6	0.00 (-0.36 to 0.36)	
Hill et al	-0.1	0.64	16	-0.1	0.64	17	1.8	0.00 (-0.44 to 0.44)	
Leelarungrayub et al	-0.04	0.55	10	-0.04	0.55	10	1.5	0.00 (-0.48 to 0.48)	
Mehani SHM	0.1	0.1	20	0	0.1	20	87.8	0.10 (0.04 to 0.16)	
Wu et al	-0.07	0.3	19	0	0.6	21	4.0	-0.07 (-0.36 to 0.22)	
Subtotal (95% CI)			92			93	100	0.08 (0.03 to 0.14)	◆
Heterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 2.00, Test for overall effect: $Z = 2.87$ ( $P = .004$		2); I <sup>2</sup> = C	)%						
•									-0.5 -0.25 0 0.25 0.5
									Favors control Favors IMT

Fig. 4. FEV<sub>1</sub> for treatment with isolated IMT against control group. IMT = inspiratory muscle training.

CI 0.03–0.16, I<sup>2</sup>: 0%). No improvement of this outcome was found in the analysis of IMT loads up to 35% of  $P_{Imax}$  (0.00, 95% CI –0.28 to 0.28, I<sup>2</sup>: 0%), and improvement occurred according to intervention duration of 6–8 weeks (0.08, 95% CI 0.03–0.14, I<sup>2</sup>: 0%).

**Vital Capacity.** Three studies<sup>29,33,42</sup> that analyzed isolated IMT and assessed vital capacity (n = 73), and no improvement was observed compared to the control groups (-0.08, 95% CI -0.81 to 0.64, I<sup>2</sup>: 0%). Based on the GRADE approach, the

quality of evidence for this result was low due to methodology limitations and inconsistency of results (Table 1).

**Distance Walked in 6MWT.** We identified 22 studies<sup>17,18,20,22,23,26,27,29,32-35,37,39-41,46-48,51,53,55</sup> that analyzed isolated IMT and assessed distance walked in 6MWT (n = 605 subjects) with significant improvement (34.28 m, 95% CI 29.43–39.14, I<sup>2</sup>: 0%) (Fig. 5). Based on the GRADE approach, the quality of evidence for this result was low due to methodology limitations and inconsistency of results (Table 1).

Study or Subgroup	Mean	periment SD		Mean	Control SD	Total	Weight, %	Mean Difference IV, Random, 95% CI	Mean Difference IV, Random, 95% CI
MW									
Ahmad et al	75	83.5	9	35	57.3	9	0.5	40.00 (-26.16 to 106.16)	
Basso-Vanelli et al	57.3	144.4	13	34.3	128	12	0.2	23.00 (-83.80 to 129.80)	
Beckerman et al	72	293.89	21	-16	283	21	0.1	88.00 (-86.50 to 262.50)	
Chuang et al	47.78	67.8	27	5.5	95.3	28	1.2	42.28 (-1.31 to 85.87)	
Cooper et al	23	120.9	9	32	103.1	7	0.2	-9.00 (-118.87 to 100.87)	
Goldstein et al	37	176.98	6	41	93.86	5	0.1	-4.00 (-167.77 to 159.77)	
Hill et al	47.78	67.8	27	5.5	95.3	28	1.2	42.28 (-1.31 to 85.87)	<u> </u>
Hsiao et al	32.3	74.5	10	12.2	98.09	10	0.4	20.10 (-56.24 to 96.44)	
Koppers et al	23	115.4	18	-5	113.35	18	0.4	28.00 (-46.73 to 102.73)	
Leelarungrayub et al	39.6	81	10	27	107.39	10	0.3	12.60 (-70.77 to 95.97)	
Lisboa et al	114	163.2	10	38	107.39	10	0.3	76.00 (-56.47 to 208.47)	
Mehani SHM	68	7.4	20	33.5	8.8	20	92.9	34.50 (29.46 to 39.54)	
								. ,	
Minoguchi et al	26	95.6	12	47	99.8	12	0.4	-21.00 (-99.19 to 57.19)	
Nikoletou et al	15.9	136.6	21	2.8	202.6	18	0.2	13.10 (-97.23 to 123.43)	
Oh	40.61	90.7	15	-27.3	81.6	8	0.4	67.91 (-4.92 to 140.74)	<u> </u>
Preusser et al	49	402.4	12	17	323.7	8	0.0	32.00 (-287.61 to 351.61) -	
Ramirez-sarmiento et al	-12	102.6	7	-22	161.9	7	0.1	10.00 (-131.99 to 151.99)	t
Sanchez Riera et al	93	164.8	10	-58	223.3	10	0.1	151.00 (-21.01 to 323.01)	+
Séron et al	-5.3	70.5	15	1.3	101.2	16	0.6	-6.60 (-67.69 to 54.49)	
Weiner et al	50	210.9	11	42	124.7	11	0.1	8.00 (-136.79 to 152.79)	
Weiner et al	71	181.5	8	-10	159.5	8	0.1	81.00 (-86.43 to 248.43)	
Weiner et al	98	229	19	16	197.7	19	0.1	82.00 (-54.03 to 218.03)	
ubtotal (95% CI)			310			295	100	34.28 (29.43 to 39.14)	•
est for overall effect: Z = 13.83 (P < .0) Vith weakness									
Ahmad et al	75	83.5	9	35	57.3	9	9.5	40.00 (-26.16 to 106.16)	+
Basso-vanelli et al	57.3	144.4	13	34.3	128	12	3.6	23.00 (-83.80 to 129.80)	
Chuang et al	47.78	67.8	27	5.5	95.3	28	21.8	42.28 (-1.31 to 85.87)	
Goldstein et al	37	176.98	6	41	93.86	5	1.5	-4.00 (-167.77 to 159.77)	
Hill et al	47.78	67.8	27	5.5	95.3	28	21.8	42.28 (-1.31 to 85.87)	
Hill et al Hsiao et al	47.78 32.3	67.8 74.5	27 10	5.5 12.2	95.3 98.09	28 10			
							21.8	42.28 (-1.31 to 85.87)	
Hsiao et al	32.3	74.5	10	12.2	98.09	10	21.8 7.1	42.28 (-1.31 to 85.87) 20.10 (-56.24 to 96.44)	
Hsiao et al Leelarungrayub et al	32.3 39.6	74.5 81	10 10	12.2 27	98.09 107.39	10 10	21.8 7.1 6.0	42.28 (-1.31 to 85.87) 20.10 (-56.24 to 96.44) 12.60 (-70.77 to 95.97)	
Hsiao et al Leelarungrayub et al Minoguchi et al	32.3 39.6 26	74.5 81 95.6	10 10 12	12.2 27 47	98.09 107.39 99.8	10 10 12	21.8 7.1 6.0 6.8	42.28 (-1.31 to 85.87) 20.10 (-56.24 to 96.44) 12.60 (-70.77 to 95.97) -21.00 (-99.19 to 57.19)	
Hsiao et al Leelarungrayub et al Minoguchi et al Nikoletou et al	32.3 39.6 26 15.9	74.5 81 95.6 136.6	10 10 12 21	12.2 27 47 2.8	98.09 107.39 99.8 202.6	10 10 12 18	21.8 7.1 6.0 6.8 3.4	42.28 (-1.31 to 85.87) 20.10 (-56.24 to 96.44) 12.60 (-70.77 to 95.97) -21.00 (-99.19 to 57.19) 13.10 (-97.23 to 123.43)	
Hsiao et al Leelarungrayub et al Minoguchi et al Nikoletou et al Preusser et al	32.3 39.6 26 15.9 49	74.5 81 95.6 136.6 402.4	10 10 12 21 12	12.2 27 47 2.8 17	98.09 107.39 99.8 202.6 323.7	10 10 12 18 8	21.8 7.1 6.0 6.8 3.4 0.4	42.28 (-1.31 to 85.87) 20.10 (-56.24 to 96.44) 12.60 (-70.77 to 95.97) -21.00 (-99.19 to 57.19) 13.10 (-97.23 to 123.43) 32.00 (-287.61 to 351.61)	
Hsiao et al Leelarungrayub et al Minoguchi et al Nikoletou et al Preusser et al Sanchez Riera et al Séron et al	32.3 39.6 26 15.9 49 93 -5.3	74.5 81 95.6 136.6 402.4 164.8	10 10 12 21 12 10	12.2 27 47 2.8 17 -58	98.09 107.39 99.8 202.6 323.7 223.3	10 10 12 18 8 10	21.8 7.1 6.0 6.8 3.4 0.4 1.4	42.28 (-1.31 to 85.87) 20.10 (-56.24 to 96.44) 12.60 (-70.77 to 95.97) -21.00 (-99.19 to 57.19) 13.10 (-97.23 to 123.43) 32.00 (-287.61 to 351.61) 151.00 (-21.01 to 323.01) -6.60 (-67.69 to 54.49)	
Hsiao et al Leelarungrayub et al Minoguchi et al Nikoletou et al Preusser et al Sanchez Riera et al Séron et al Weiner et al	32.3 39.6 26 15.9 49 93	74.5 81 95.6 136.6 402.4 164.8 70.5	10 10 12 21 12 10 15	12.2 27 47 2.8 17 -58 1.3	98.09 107.39 99.8 202.6 323.7 223.3 101.2 124.7	10 10 12 18 8 10 16	21.8 7.1 6.0 6.8 3.4 0.4 1.4 11.1	42.28 (-1.31 to 85.87) 20.10 (-56.24 to 96.44) 12.60 (-70.77 to 95.97) -21.00 (-99.19 to 57.19) 13.10 (-97.23 to 123.43) 32.00 (-287.61 to 351.61) 151.00 (-21.01 to 323.01) -6.60 (-67.69 to 54.49) 8.00 (-136.79 to 152.79)	
Hsiao et al Leelarungrayub et al Minoguchi et al Nikoletou et al Preusser et al Sanchez Riera et al Séron et al Weiner et al Weiner et al	32.3 39.6 26 15.9 49 93 -5.3 50 71	74.5 81 95.6 136.6 402.4 164.8 70.5 210.9 181.5	10 10 12 21 12 10 15 11 8	12.2 27 47 2.8 17 -58 1.3 42	98.09 107.39 99.8 202.6 323.7 223.3 101.2 124.7 159.5	10 10 12 18 8 10 16 11 8	21.8 7.1 6.0 6.8 3.4 0.4 1.4 11.1 2.0 1.5	42.28 (-1.31 to 85.87) 20.10 (-56.24 to 96.44) 12.60 (-70.77 to 95.97) -21.00 (-99.19 to 57.19) 13.10 (-97.23 to 123.43) 32.00 (-287.61 to 351.61) 151.00 (-21.01 to 323.01) -6.60 (-67.69 to 54.49) 8.00 (-136.79 to 152.79) 81.00 (-86.43 to 248.43)	
Hsiao et al Leelarungrayub et al Minoguchi et al Nikoletou et al Preusser et al Sanchez Riera et al Séron et al Weiner et al Weiner et al	32.3 39.6 26 15.9 49 93 -5.3 50	74.5 81 95.6 136.6 402.4 164.8 70.5 210.9	10 10 12 21 12 10 15 11 8 19	12.2 27 47 2.8 17 -58 1.3 42 -10	98.09 107.39 99.8 202.6 323.7 223.3 101.2 124.7	10 10 12 18 8 10 16 11 8 19	21.8 7.1 6.0 6.8 3.4 1.4 11.1 2.0 1.5 2.2	42.28 (-1.31 to 85.87) 20.10 (-56.24 to 96.44) 12.60 (-70.77 to 95.97) -21.00 (-99.19 to 57.19) 13.10 (-97.23 to 123.43) 32.00 (-287.61 to 351.61) 151.00 (-21.01 to 323.01) -6.60 (-67.69 to 54.49) 8.00 (-136.79 to 152.79) 81.00 (-86.43 to 248.43) 82.00 (-54.03 to 248.03)	
Hsiao et al Leelarungrayub et al Minoguchi et al Nikoletou et al Preusser et al Sanchez Riera et al Séron et al Weiner et al Weiner et al	32.3 39.6 26 15.9 49 93 -5.3 50 71 98 1, df = 14 ( <i>P</i> = .5	74.5 81 95.6 136.6 402.4 164.8 70.5 210.9 181.5 229	10 10 12 21 12 10 15 11 8 19 210	12.2 27 47 2.8 17 -58 1.3 42 -10	98.09 107.39 99.8 202.6 323.7 223.3 101.2 124.7 159.5	10 10 12 18 8 10 16 11 8	21.8 7.1 6.0 6.8 3.4 0.4 1.4 11.1 2.0 1.5	42.28 (-1.31 to 85.87) 20.10 (-56.24 to 96.44) 12.60 (-70.77 to 95.97) -21.00 (-99.19 to 57.19) 13.10 (-97.23 to 123.43) 32.00 (-287.61 to 351.61) 151.00 (-21.01 to 323.01) -6.60 (-67.69 to 54.49) 8.00 (-136.79 to 152.79) 81.00 (-86.43 to 248.43)	
Hsiao et al Leelarungrayub et al Minoguchi et al Nikoletou et al Preusser et al Sanchez Riera et al Séron et al Weiner et al Weiner et al Subtotal (95% CI) leterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 7.11 est for overall effect: $Z = 2.78$ ( $P = .00$	32.3 39.6 26 15.9 93 -5.3 50 71 98 9. df = 14 ( <i>P</i> = .9 05)	74.5 81 95.6 136.6 402.4 164.8 70.5 210.9 181.5 229 03); I <sup>2</sup> = 0	10 10 12 21 12 10 15 11 8 19 210 %	12.2 27 47 2.8 17 -58 1.3 42 -10 16	98.09 107.39 99.8 202.6 323.7 223.3 101.2 124.7 159.5 197.7	10 10 12 18 8 10 16 11 8 19 204	21.8 7.1 6.0 6.8 3.4 1.4 11.1 2.0 1.5 2.2 100	42.28 (-1.31 to 85.87) 20.10 (-56.24 to 96.44) 12.60 (-70.77 to 95.97) -21.00 (-99.19 to 57.19) 13.10 (-97.23 to 123.43) 32.00 (-287.61 to 351.61) 151.00 (-21.01 to 323.01) -6.60 (-67.69 to 54.49) 8.00 (-136.79 to 152.79) 81.00 (-86.43 to 248.43) 82.00 (-54.03 to 218.03) 28.87 (8.53 to 49.22)	
Hsiao et al Leelarungrayub et al Minoguchi et al Nikoletou et al Preusser et al Sanchez Riera et al Séron et al Weiner et al Weiner et al Weiner et al Jubtotal (95% Cl) leterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 7.11 est for overall effect: $Z = 2.78$ ( $P = .00$ ) Vithout weakness Beckerman et al	32.3 39.6 26 15.9 93 -5.3 50 71 98 1, df = 14 ( <i>P</i> = . 55)	74.5 81 95.6 136.6 402.4 164.8 70.5 210.9 181.5 229 03); I <sup>2</sup> = 0 293.89	10 10 12 21 12 10 15 11 8 19 210 %	12.2 27 47 2.8 17 -58 1.3 42 -10 16	98.09 107.39 99.8 202.6 323.7 223.3 101.2 124.7 159.5 197.7 283	10 10 12 18 8 10 16 11 8 19 204	21.8 7.1 6.0 6.8 3.4 0.4 1.4 11.1 2.0 1.5 2.2 100	42.28 (-1.31 to 85.87) 20.10 (-56.24 to 96.44) 12.60 (-70.77 to 95.97) -21.00 (-99.19 to 57.19) 13.10 (-97.23 to 123.43) 32.00 (-287.61 to 351.61) 151.00 (-21.01 to 323.01) -6.60 (-67.69 to 54.49) 8.00 (-136.79 to 152.79) 81.00 (-86.43 to 248.43) 82.00 (-54.03 to 218.03) 28.87 (8.53 to 49.22) 888.00 (-86.50 to 262.50)	
Hsiao et al Leelarungrayub et al Minoguchi et al Nikoletou et al Preusser et al Sanchez Riera et al Séron et al Weiner et al Weiner et al Weiner et al Weiner et al Subtotal (95% Cl) Idetorogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 7.11 Test for overall effect: Z = 2.78 ( $P$ = .00) Vithout weakness Beckerman et al Cooper et al	32.3 39.6 26 15.9 93 -5.3 50 71 98 1, df = 14 (P = .9 25) 72 23	74.5 81 95.6 136.6 402.4 164.8 70.5 210.9 181.5 229 03); I <sup>2</sup> = 0 293.89 120.9	10 10 12 21 10 15 11 8 9 210 %	12.2 27 47 2.8 17 -58 1.3 42 -10 16	98.09 107.39 99.8 202.6 323.7 223.3 101.2 124.7 159.5 197.7 283 103.1	10 10 12 18 8 10 16 11 8 9 204 21 7	21.8 7.1 6.0 6.8 3.4 0.4 1.4 1.1 2.0 1.5 2.2 100 0.1 0.2	42.28 (-1.31 to 85.87) 20.10 (-56.24 to 96.44) 12.60 (-70.77 to 95.97) -21.00 (-99.19 to 57.19) 13.10 (-97.23 to 123.43) 32.00 (-287.61 to 351.61) 151.00 (-21.01 to 323.01) -6.60 (-67.69 to 54.49) 8.00 (-136.79 to 152.79) 81.00 (-86.43 to 248.43) 82.00 (-54.03 to 218.03) 28.87 (8.53 to 49.22) 88.00 (-86.50 to 262.50) -9.00 (-118.87 to 100.87)	
Hsiao et al Leelarungrayub et al Minoguchi et al Nikoletou et al Preusser et al Sanchez Riera et al Séron et al Weiner et al Weiner et al Weiner et al Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 7.11 est for overall effect: $Z = 2.78$ ( $P = .00$ Vithout weakness Beckerman et al Cooper et al Koppers et al	32.3 39.6 26 15.9 93 -5.3 50 71 98 1, df = 14 (P = .5 55) 72 23 23	74.5 81 95.6 136.6 402.4 164.8 70.5 210.9 181.5 229 03); I <sup>2</sup> = 0 293.89 120.9 115.4	10 10 12 21 12 10 15 11 8 19 210 % 21 9 18	12.2 27 47 2.8 17 -58 1.3 42 -10 16	98.09 107.39 99.8 202.6 323.7 223.3 101.2 124.7 159.5 197.7 283 103.1 113.35	10 10 12 18 8 10 16 11 8 19 204 21 7 18	21.8 7.1 6.0 6.8 3.4 0.4 1.4 1.1 2.0 1.5 2.2 100 0.1 0.2 0.4	42.28 (-1.31 to 85.87) 20.10 (-56.24 to 96.44) 12.60 (-70.77 to 95.97) -21.00 (-99.19 to 57.19) 13.10 (-97.23 to 123.43) 32.00 (-287.61 to 351.61) -6.60 (-67.69 to 54.49) 8.00 (-136.79 to 152.79) 81.00 (-86.43 to 248.43) 82.00 (-54.03 to 218.03) 28.87 (8.53 to 49.22) 88.00 (-86.50 to 262.50) -9.00 (-118.87 to 100.87) 28.00 (-46.73 to 102.73)	
Hsiao et al Leelarungrayub et al Minoguchi et al Nikoletou et al Preusser et al Sanchez Riera et al Séron et al Weiner et al Weiner et al Weiner et al Weiner et al Ubtotal (95% CI) leterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 7.11 est for overall effect: Z = 2.78 ( $P$ = .00 Vithout weakness Beckerman et al Cooper et al Koppers et al Lisboa et al	32.3 39.6 26 15.9 93 -5.3 50 71 98 1, df = 14 ( <i>P</i> = . 25) 72 23 23 23 114	74.5 81 95.6 136.6 402.4 164.8 70.5 210.9 181.5 229 03); I <sup>2</sup> = 0 293.89 120.9 115.4 163.2	10 10 12 21 12 10 15 11 8 19 210 %	12.2 27 47 2.8 17 -58 1.3 42 -10 16	98.09 107.39 99.8 202.6 323.7 223.3 101.2 124.7 159.5 197.7 283 103.1 113.35 138	10 10 12 18 8 10 16 11 8 19 204 21 7 18 10	21.8 7.1 6.0 6.8 3.4 0.4 1.4 11.1 2.0 1.5 2.2 100 0.1 0.1 0.2 0.4 0.1	42.28 (-1.31 to 85.87) 20.10 (-56.24 to 96.44) 12.60 (-70.77 to 95.97) -21.00 (-99.19 to 57.19) 13.10 (-97.23 to 123.43) 32.00 (-287.61 to 351.61) -6.60 (-67.69 to 54.49) 8.00 (-136.79 to 152.79) 81.00 (-86.43 to 248.43) 82.00 (-54.03 to 218.03) 28.87 (8.53 to 49.22) 88.00 (-86.50 to 262.50) -9.00 (-118.87 to 100.87) 28.00 (-46.73 to 102.73) 76.00 (-56.47 to 208.47)	
Hsiao et al Leelarungrayub et al Minoguchi et al Nikoletou et al Preusser et al Sanchez Riera et al Séron et al Weiner et al Weiner et al Ubtotal (95% Cl) leterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 7.11 est for overall effect: $Z = 2.78$ ( $P = .00$ ) Vithout weakness Beckerman et al Cooper et al Koppers et al Lisboa et al Mehani SHM	32.3 39.6 26 15.9 93 -5.3 50 71 98 1, df = 14 ( <i>P</i> = . 23 23 23 114 68	$\begin{array}{c} 74.5\\ 81\\ 95.6\\ 136.6\\ 402.4\\ 164.8\\ 70.5\\ 210.9\\ 181.5\\ 229\\ 33); \ l^2=0\\ 293.89\\ 120.9\\ 115.4\\ 163.2\\ 7.4 \end{array}$	10 10 12 21 12 10 15 11 8 19 210 % 210 %	12.2 27 47 -58 1.3 42 -10 16 -16 32 -5 38 33.5	98.09 107.39 99.8 202.6 323.7 223.3 101.2 124.7 159.5 197.7 283 103.1 113.35 138 8.8	10 10 12 18 8 10 16 11 8 19 204 21 7 18 10 20	21.8 7.1 6.0 6.8 3.4 0.4 1.4 11.1 2.0 1.5 2.2 100 0.1 0.2 0.4 0.1 98.6	42.28 (-1.31 to 85.87) 20.10 (-56.24 to 96.44) 12.60 (-70.77 to 95.97) -21.00 (-99.19 to 57.19) 13.10 (-97.23 to 123.43) 32.00 (-287.61 to 351.61) 151.00 (-21.01 to 323.01) -6.60 (-67.69 to 54.49) 8.00 (-136.79 to 152.79) 81.00 (-86.43 to 248.43) 82.00 (-54.03 to 218.03) 28.87 (8.53 to 49.22) 888.00 (-86.50 to 262.50) -9.00 (-118.87 to 100.87) 28.00 (-56.47 to 208.47) 34.50 (29.46 to 39.54)	
Hsiao et al Leelarungrayub et al Minoguchi et al Nikoletou et al Preusser et al Sanchez Riera et al Séron et al Weiner et al Weiner et al Weiner et al Weiner et al Ubtotal (95% CI) leterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 7.11 est for overall effect: Z = 2.78 ( $P$ = .00 Vithout weakness Beckerman et al Cooper et al Koppers et al Lisboa et al	32.3 39.6 26 15.9 93 -5.3 50 71 98 1, df = 14 ( <i>P</i> = . 25) 72 23 23 23 114	74.5 81 95.6 136.6 402.4 164.8 70.5 210.9 181.5 229 03); I <sup>2</sup> = 0 293.89 120.9 115.4 163.2	10 10 12 21 12 10 15 11 8 19 210 %	12.2 27 47 2.8 17 -58 1.3 42 -10 16	98.09 107.39 99.8 202.6 323.7 223.3 101.2 124.7 159.5 197.7 283 103.1 113.35 138	10 10 12 18 8 10 16 11 8 19 204 21 7 18 10	21.8 7.1 6.0 6.8 3.4 0.4 1.4 11.1 2.0 1.5 2.2 100 0.1 0.1 0.2 0.4 0.1	42.28 (-1.31 to 85.87) 20.10 (-56.24 to 96.44) 12.60 (-70.77 to 95.97) -21.00 (-99.19 to 57.19) 13.10 (-97.23 to 123.43) 32.00 (-287.61 to 351.61) -6.60 (-67.69 to 54.49) 8.00 (-136.79 to 152.79) 81.00 (-86.43 to 248.43) 82.00 (-54.03 to 218.03) 28.87 (8.53 to 49.22) 88.00 (-86.50 to 262.50) -9.00 (-118.87 to 100.87) 28.00 (-46.73 to 102.73) 76.00 (-56.47 to 208.47)	

Fig. 5. 6MWT for treatment with isolated IMT against control group. IMT = inspiratory muscle training; 6MWT = 6-min-walk test.

There was significant improvement for this outcome in the 15 studies that only included subjects with inspiratory muscle weakness<sup>17,18,22,23,26,27,32-34,37,40,41,46-48</sup> (28.87 m, 95% CI 8.53–49.22, I<sup>2</sup>: 0%), and the increase was higher in subjects without respiratory muscle weakness (34.64 m, 95% CI 29.64–39.65 I<sup>2</sup>: 0%). When IMT loads of 40–50% of P<sub>Imax</sub> were analyzed, there was no significant improvement (21.94 m, 95% CI –10.74 to 54.62, I<sup>2</sup>: 0%); however, this outcome showed improvement in IMT loads superior to 60–80% (34.72 m, 95% CI 29.72–39.73, I<sup>2</sup>: 0%). In relation to intervention duration, no improvement was observed

for this outcome in studies that carried out the intervention for 4 weeks (20.76 m, 95% CI 12.24 to 53.77,  $I^2$ : 0%), and the same occurred for interventions that lasted 10–12 weeks (59.05 m, 95% CI 14.88 to 132.97,  $I^2$ : 0%. The results were different for interventions of 6–8 weeks, which showed significant improvement (34.46 m, 95% CI 29.54–39.38,  $I^2$ : 0%). In meta-regression analyses, no tested covariates were able to explain the heterogeneity observed (data not shown).

While analyzing studies that performed IMT associated with other interventions, 5 studies<sup>57,62-65</sup> assessed 6MWT

		erimental		ontrol		Mean Difference	Mean Difference
Study or Subgroup	Mean	SD Total	Mean	SD Tot	al Weight, %	IV, Random, 95% CI	IV, Random, 95% CI
6MWT							
Beaumont et al	23.4 1	22.9 74	36.2 1	05.9 7	5 28.0	( /	
Beaumont et al	24.9 2	86.9 16	47.6 2	72.5 1	8 2.6	-22.70 (-211.41 to 166.01)	
Dellweg et al	196	81.5 15	103	99.6 1	4 14.9	93.00 (26.49 to 159.51)	
Schultz et al	85.3 1	29.9 300	84 1	32.5 30	2 37.9	1.30 (-19.66 to 22.26)	+
Wang et al	21.7 1	03.1 28	32.5 1	26.9 2	7 16.6	-10.80 (-72.03 to 50.43)	
Subtotal (95% CI)		433		43	6 100	8.40 (-22.90 to 39.71)	<b>•</b>
Heterogeneity: Tau <sup>2</sup> = 55	8.77; Chi <sup>2</sup> = 8.0	03, df = 4 (F	P = .09); I <sup>2</sup>	= 50%			
Test for overall effect: Z =	= 0.53 ( <i>P</i> = .60)	)					
3–4 weeks							
Beaumont et al	23.4 1	22.9 74	36.2 1	05.9 7	5 33.7	-12.80 (-49.66 to 24.06)	
Beaumont et al	24.9 2	86.9 16	47.6 2	72.5 1	8 4.0	-22.70 (-211.41 to 166.01)	
Dellweg et al	196	81.5 15	103	99.6 1	4 20.2	93.00 (26.49 to 159.51)	
Schultz et al	85.3 1	29.9 300	84 1	32.5 30	2 42.2	1.30 (-19.66 to 22.26)	
Subtotal (95% CI)		405		40	9 100	14.10 (-25.16 to 53.35)	
Heterogeneity: Tau <sup>2</sup> = 83	6.85; Chi <sup>2</sup> = 7.8	32, df = 3 (F	P = .05); I <sup>2</sup>	= 62%			
Test for overall effect: Z =	= 0.70 ( <i>P</i> = .48)	)					
Without weakness							
Beaumont et al	23.4 1	22.9 74	36.2 1	05.9 7	5 24.2	-12.80 (-49.66 to 24.06)	
Beaumont et al	24.9 2	86.9 16	47.6 2	72.5 1	8 0.9	-22.70 (-211.41 to 166.01)	
Schultz et al	85.3 1	29.9 300	84 1	32.5 30	2 74.9	1.30 (-19.66 to 22.26)	
Subtota (95% CI)		390		39	5 100	-2.34 (-20.47 to 15.80)	<b>+</b>
Heterogeneity: Tau <sup>2</sup> = 0.0	00; Chi <sup>2</sup> = 0.47,	df = 2 (P =	.79); l <sup>2</sup> = 0	0%			
Test for overall effect: Z =	= 0.25 (P = .80)	)					
							-200 -100 0 100 2
							-200 -100 0 100 2 Favors control Favors IMT

Fig. 6. 6MWT for treatment with associated IMT against control group. IMT = inspiratory muscle training; 6MWT = 6-min-walk test.

(n = 869 subjects), and no significant difference was observed for this outcome (8.40 m, 95% CI –22.90 to 39.71, I<sup>2</sup>: 50%) (Fig. 6). Based on GRADE, quality of evidence for this outcome was considered moderate due to methodology limitations, imprecision and inconsistency of results (Table 1). No improvement was observed for this outcome in studies that carried out the intervention for 3 to 4 weeks (14.10 m [95% CI: –25.16 to 53.35; I<sup>2</sup>: 62%]). In sensitivity analysis of studies that included subjects without inspiratory muscle weakness,<sup>62,64,65</sup> significant improvement was observed in 6MWT in favor of the control group when compared to IMT (–2,34 m [95% CI: –20.47 to 15.80; I<sup>2</sup>: 0%]).

**Maximum Oxygen Consumption.** Three studies<sup>36,40,44</sup> that analyzed isolated IMT assessed maximum oxygen consumption ( $\dot{V}_{O_2}$ ) (n = 82 subjects), and no difference was observed for this outcome (0.12 mL/kg/min, 95% CI –0.14 to 0.39, I<sup>2</sup> 0%). Based on the GRADE approach, the quality of evidence for this result was considered very low due to methodology limitations and inconsistency of results (Table 1). In 3 studies<sup>58-60</sup> that conducted IMT associated with other intervention and assessed  $\dot{V}_{O_2}$  (n = 96 subjects), no difference was observed (-0.02 mL/kg/min, 95% CI -0.22 to 0.19, I<sup>2</sup>: 0%). All studies included subjects that had respiratory muscle weakness. Based on the GRADE approach, the quality of evidence for this result was considered low due to methodology limitations and inconsistency of results (Table 1). Dyspnea. We identified 12 studies<sup>29,30,32,33,35,36,40,41,46-48,51</sup> that conducted isolated IMT and assessed dyspnea with the Borg scale (n = 280 subjects), and no significant difference was observed (-0.37, 95% CI -1.21 to 0.47, I<sup>2</sup>: 58%) (see the supplementary materials at http://www.rcjournal.com). Based on the GRADE approach, the quality of evidence for this result was considered very low due to methodology limitations and inconsistency of results (Table 1). The studies that only assessed subjects with inspiratory muscle weakness<sup>32,33,40,46-48</sup> reported significant improvement for this outcome and an absence of heterogeneity (0.59, 95% CI -0.00 to 1.18, I<sup>2</sup>: 0%). For subjects without respiratory muscle weakness, no improvement was observed for this outcome (-1.27, 95% CI -2.67 to 0.12, I<sup>2</sup>: 69%)]. The analysis of studies with IMT loads of 40-50% (0.45, 95% CI -0.36 to 1.26, I<sup>2</sup>: 38%) and 60–80% (0.18, 95% CI –0.93 to 1.29, I<sup>2</sup>: 0%) showed no significant improvement for this outcome. Studies with intervention durations of 4 weeks (-0.83, 95%)CI -1.88 to 0.22, I<sup>2</sup>: 20%) and 6-8 weeks (-0.26, 95%) CI -1.29 to 0.76, I<sup>2</sup>: 67%) reported no significant improvement.

**Quality of Life.** We identified 2 studies<sup>17,20</sup> that conducted isolated IMT and assessed quality of life (n = 60 subjects) with loads of 60–80%, and no significant difference was observed for this outcome (18.85, 95% CI –8.00 to 45.70, I<sup>2</sup>: 0%) (see the supplementary materials at http://www.rcjournal. com). Based on the GRADE approach, the quality of evidence

for this result was considered very low due to methodology limitations and inconsistency of results (Table 1).

### Discussion

# Summary of Evidence

This systematic review and meta-analysis indicates that isolated IMT improves inspiratory muscle strength, functional capacity, and pulmonary function, without difference in dyspnea and quality of life. IMT associated with other interventions, on the other hand, presented increases only in inspiratory muscle strength.

Significant improvement in the distance walked in the 6MWT was observed only for isolated IMT; in subjects without respiratory muscle weakness, the increase was higher. In addition, this improvement can be considered to be a clinically relevant difference for patients with COPD, for whom one of the major limitations is functional capacity.

With regard to  $V_{O_2}$ , dyspnea, and quality of life, there was no significant difference. Moreover, gains were higher in studies that included subjects with inspiratory muscle weakness, conducted IMT for  $\geq 8$  weeks, and had control groups that received placebo IMT without load<sup>40</sup> or with very low inspiratory load.<sup>20,24-27,30,31,35-37,41-43,46-49,60,61</sup> This may be due to the higher level of deficiency in subjects included, longer duration of intervention, and the comparison of an IMT group with a control group that received placebo IMT without inspiratory load. Two studies indicated that dyspnea and distance walked on the 6MWT are inversely proportional, which probably correlates with improvement in exercise capacity.<sup>66,67</sup>

This meta-analysis observed divergent results for functional capacity. We noted a significant increase in distance walked in the 6MWT (with isolated IMT), which did not occur for maximum  $\dot{V}_{O_2}$ . This result may be explained by the fact that maximum and submaximum tests have different physiological determinants and the potential for postintervention improvement.<sup>68</sup> Moreover, in the maximum  $\dot{V}_{O_2}$ analysis, there was a small number of subjects and, according to the GRADE approach, the quality of evidence for this result was considered very low due to methodology limitations, imprecision, and inconsistency of results.

We also observed that IMT significantly improved  $P_{Imax}$  compared to control groups. Several studies noted that  $P_{Imax}$  is reduced in subjects with COPD,<sup>10</sup> and that IMT has a beneficial effect on this outcome.<sup>17,18,32,57</sup> Improvement in inspiratory muscle function may have reached respiratory discharge with restoration of unbalance between inspiratory muscles capacity to sustain the activity and inspiratory loads. There is evidence that respiratory muscle weakness, observed in subjects with COPD, is improved. Moreover, this variable is directly correlated to  $\dot{V}_{O_2}$ , which suggests

that respiratory muscle weakness contributes to the deficit in exercise capacity under COPD.<sup>69</sup>

Another important aspect concerns the loads analyzed in these studies, which ranged from 30% to 60% of  $P_{Imax}$ . In the study by Basso-Vanelli et al,<sup>18</sup> which started IMT with initial load of 10 cm H<sub>2</sub>O and progressed to 60% of  $P_{Imax}$  after intervention, there was significant improvement in both groups with regard to respiratory muscle resistance and strength, thoracic-abdominal mobility and distance walked in the 6MWT. There was also reduction of dyspnea at 6MWT peak.

Corroborating the above mentioned results, Beckerman et al<sup>20</sup> observed, while using IMT load of 15–60% of  $P_{Imax}$ , statistically significant increases in inspiratory muscle strength and distance walked in the 6MWT by the end of the third month of training and reduction of dyspnea by the end of 9 months of training in the intervention group, but these increases were not seen in the control group. By the end of one year of training, these changes were maintained.

### **Strengths and Limitations**

This meta-analysis of RCTs was conducted to quantitatively express the results and to assess the quality of evidence for each outcome analyzed. We noted that the RCTs included were methodologically limited because none of them presented in full the items observed in the bias risk assessment. Another limitation is that few studies evaluated IMT for an intervention time > 10 weeks, making it difficult to discuss our results and reinforcing the need for further studies evaluating the effect of IMT in the long term. Nevertheless, there were reasonably large numbers of studies and subjects, which makes our study relevant.

According to the GRADE approach, all results, except for FEV<sub>1</sub> outcome (IMT isolated),  $P_{Imax}$ , and 6MWT (IMT associated), which were considered moderate, presented low or very low quality of evidence. This indicates that any estimate of effect is very uncertain, and it is likely that new research will improve the confidence to estimate the effect.

### **Comparisons with Other Reviews**

Gosselink et al<sup>10</sup> performed a systematic review on this subject. However, this work included 32 RCTs that used IMT in subjects with COPD, whereas the present review included 46 papers that used IMT in subjects with COPD. Additionally, Gosselink et al<sup>10</sup> limited their search for papers in English, whereas the current review did not have language limitations. Moreover, the meta-analyses analyzed here considered the type of device used, dyspnea outcome with the Borg scale, exercise capacity with the 6MWT, and quality of life with the St George Respiratory Questionnaire for subjects with COPD, which Gosselink et al<sup>10</sup> did not do. For these reasons, some studies included in

Copyright (C) 2020 Daedalus Enterprises ePub ahead of print papers have been peer-reviewed, accepted for publication, copy edited and proofread. However, this version may differ from the final published version in the online and print editions of RESPIRATORY CARE

in the meta-analysis by Gosselink et al<sup>10</sup> were excluded from our review because they did not meet our eligibility criteria or presented incomplete data, which hampered statistical analyses.

The systematic review carried out by Beaumont et al,<sup>11</sup> which verified IMT effects in subjects with COPD regarding dyspnea, quality of life, exercise capacity, and inspiratory muscle strength, included 43 studies, with 37 metaanalyses, but the search was limited to studies in English and French. The number of studies included was similar to that of this review, although Beaumont et al<sup>11</sup> included nonrandomized controlled trials and cohort studies in addition to RCTs, which may compromise the quality of the evidence. Our review generates a higher level of evidence against already existing evidence.

We observed that all of above-mentioned reviews assessed P<sub>Imax</sub> and functional capacity with the 6MWT, with positive results for these outcomes, which corroborate our review. Our review assessed outcomes associated to with pulmonary function (ie, FVC, FEV<sub>1</sub>, maximum  $V_{O_2}$ , and vital capacity), and the results are inconclusive because we found differences only for FEV<sub>1</sub>. Quality of life showed positive results as assessed in both previous reviews<sup>10,11</sup>; this differs from our results, which did not present significant improvement for this outcome. Both previous reviews<sup>10,11</sup> assessed dyspnea and found positive results; however, we noted dyspnea improvement only in studies of subjects with inspiratory muscle weakness, showing significant improvement for this outcome and absence of heterogeneity. For most outcomes presented in this review, the evidence level is still low or very low, which indicates the need for more studies on the subject.

### Conclusions

Isolated IMT is an effective treatment modality to improve inspiratory muscle strength, functional capacity, and pulmonary function in patients with COPD, without changes in dyspnea and quality of life. The presence of inspiratory muscle weakness did not change the results. Higher loads promoted a greater improvement of these outcomes. Shorter intervention times increased inspiratory muscle strength, but longer intervention times were required to increase functional capacity. Associated IMT only showed increases in inspiratory muscle strength. This analysis indicates that isolated IMT can be considered as an adjuvant intervention in patients with COPD.

#### REFERENCES

 Global Strategy for the Diagnosis, Management and Prevention of COPD. Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2017. Available at: http://goldcopd.org. Accessed on June 1, 2018.

- Halpin DM, Decramer M, Celli B, Kesten S, Liu D, Tashkin DP. Exacerbation frequency and course of COPD. Int J Chron Obstruct Pulmon Dis 2012(7):653-661.
- Mantero M, Radovanovic D, Santus P, Blasi F. Management of severe COPD exacerbations: focus on beclomethasone dipropionate/formoterol/glycopyrronium bromide. Int J Chron Obstruct Pulmon Dis 2018;13:2319-2333.
- Behnia M, Wheatley C, Avolio A, Johnson B. Influence of resting lung diffusion on exercise capacity in patients with COPD. BMC Pulm Med 2017;17(1):117.
- Sanseverino MA, Pecchiari M, Bona RL, Berton DC, de Queiroz FB, Gruet M, et al. Limiting factors in walking performance of subjects with COPD. Respir Care 2018;63(3):301-310.
- Rocha A, Arbex FF, Sperandio PA, Souza A, Biazzim L, Mancuso F, et al. Excess ventilation in chronic obstructive pulmonary diseaseheart failure overlap. implications for dyspnea and exercise intolerance. Am J Respir Crit Care Med 2017;196(10):1264-1274.
- Charususin N, Gosselink R, Decramer M, McConnell A, Saey D, Maltais F, et al. Inspiratory muscle training protocol for patients with chronic obstructive pulmonary disease (IMTCO study): a multicentre randomised controlled trial. BMJ Open 2013;3(8):e003101.
- Puhan MA, Gimeno-Santos E, Cates CJ, Troosters T. Pulmonary rehabilitation following exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2016;12(12):CD005305.
- Borge CR, Hagen KB, Mengshoel AM, Omenaas E, Moum T, Wahl AK. Effects of controlled breathing exercises and respiratory muscle training in people with chronic obstructive pulmonary disease: results from evaluating the quality of evidence in systematic reviews. BMC Pulm Med 2014;14:184.
- Gosselink R, De Vos J, van den Heuvel SP, Segers J, Decramer M, Kwakkel G. Impact of inspiratory muscle training in patients with COPD: what is the evidence? Eur Respir J 2011;37(2):416-425.
- Beaumont M, Forget P, Couturaud F, Reychler G. Effects of inspiratory muscle training in COPD patients: a systematic review and metaanalysis. Clin Respir J 2018;12(7):2178-2188.
- Higgins J, Green S. Cochrane handbook for systematic reviews of interventions, 5th ed. Chichester: John Wiley & Sons; 2011.
- Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg 2010;8(5):336-341.
- Robinson KA, Dickersin K. Development of a highly sensitive search strategy for the retrieval of reports of controlled trials using PubMed. Int J Epidemiol 2002;31(1):150-153.
- Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-560.
- Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336 (7650):924-926.
- Ahmad H, Justine M, Othman Z, Mohan V, Mirza FT. The outcomes of short term inspiratory muscle training (IMT) combined with chest physiotherapy in hospitalized COPD patients. Bangladesh J Med Sci 2013;12(4):398-404.
- Basso-Vanelli R, Lorenzo V, Labadessa I, Regueiro E, Jamami M, Gomes E, et al. Effects of inspiratory muscle training and calisthenicsand-breathing exercises in COPD with and without respiratory muscle weakness. Respir Care 2016;61(1):50-60.
- Belman MJ, Shadmehr R. Targeted resistive ventilatory muscle training in chronic obstructive pulmonary disease. J Appl Physiol 1988;65 (6):2726-2735.
- Beckerman M, Magadle R, Weiner M, Weiner P. The effects of 1 year of specific inspiratory muscle training in patients with COPD. Chest 2005;128(5):3177-3182.

## Respiratory Care $\bullet \bullet \bullet$ Vol $\bullet \bullet No \bullet$

- Bustamante Madariaga V, Gáldiz Iturri JB, Gorostiza Manterola A, Camino Buey J, Talayero Sebastián N, Sobradillo Peña V. [Comparison of 2 methods for inspiratory muscle training in patients with chronic obstructive pulmonary disease]. Arch Bronconeumol 2007;43(8):431-438.
- Chuang HY, Chang HY, Fang YY, Guo SE. The effects of threshold inspiratory muscle training in patients with chronic obstructive pulmonary disease: a randomised experimental study. J Clin Nurs 2017;26 (23-24):4830-4838.
- Goldstein R, De Rosie J, Long S, Dolmage T, Avendano MA. Applicability of a threshold loading device for inspiratory muscle testing and training in patients with COPD. Chest 1989;96(3):564-571.
- Harver A, Mahler DA, Daubenspeck JA. Targeted inspiratory muscle training improves respiratory muscle function and reduces dyspnea in patients with chronic obstructive pulmonary disease. Ann Intern Med 1989;111(2):117-124.
- Heydari A, Farzad M, Ahmadi HS. Comparing inspiratory resistive muscle training with incentive spirometry on rehabilitation of COPD patients. Rehabil Nurs 2015;40(4):243-248.
- Hill K, Jenkins S, Philippe D, Cecins N, Shepherd K, Green D, et al. High-intensity inspiratory muscle training in COPD. Eur Respir J 2006;27(6):1119-1128.
- Hsiao S, Wu Y, Wu H, Wang T. Comparison of effectiveness of pressure threshold and targeted resistance devices for inspiratory muscle training in patients with chronic obstructive pulmonary disease. J Formos Med Assoc 2003;102(4):240-245.
- Kim MJ, Larson JL, Covey MK, Vitalo CA, Alex CG, Patel M. Inspiratory muscle training in patients with chronic obstructive pulmonary disease. Nurs Res 1993;42(6):356-362.
- Koppers R, Vos P, Boot C, Folgering H. Exercise performance improves in patients with COPD due to respiratory muscle endurance training. Chest 2006;129(4):886-892.
- Langer D, Charususin N, Jácome C, Hoffman M, McConnell A, Decramer M, et al. Efficacy of a novel method for inspiratory muscle training in people with chronic obstructive pulmonary disease. Phys Ther 2015;95(9):1264-1273.
- Larson JL, Kim MJ, Sharp JT, Larson DA. Inspiratory muscle training with a pressure threshold breathing device in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis 1988;138(3):689-696.
- 32. Leelarungrayub J, Pinkaew D, Puntumetakul R, Klaphajone J. Effects of a simple prototype respiratory muscle trainer on respiratory muscle strength, quality of life and dyspnea, and oxidative stress in COPD patients: a preliminary study. Int J Chron Obstruct Pulmon Dis 2017;12:1415-1425.
- Minoguchi H, Shibuya M, Miyagawa T, Kokubu F, Yamada M, Tanaka H, et al. Cross-over comparison between respiratory muscle stretch gymnastics and inspiratory muscle training. Intern Med 2002;41(10):805-812.
- 34. Nikoletou D, Man WD, Mustfa N, Moore J, Rafferty G, Grant RL, et al. Evaluation of the effectiveness of a home-based inspiratory muscle training programme in patients with chronic obstructive pulmonary disease using multiple inspiratory muscle tests. Disabil Rehabil 2016;38(3):250-259.
- Oh E. The effects of home-based pulmonary rehabilitation in patients with chronic lung disease. Int J Nurs Stud 2003;40(8):873-879.
- Petrovic M, Reiter M, Zipko H, Pohl W, Wanke T. Effects of inspiratory muscle training on dynamic hyperinflation in patients with COPD. Int J Chron Obstruct Pulmon Dis 2012;7:797-805.
- Preusser BA, Winningham ML, Clanton TL. High- vs low-intensity inspiratory muscle interval training in patients with COPD. Chest 1994;106(1):110-117.
- Quintero JI, Borzone G, Leiva A, Villafranca C, Lisboa C. Effects of inspiratory muscle training on the oxygen cost of breathing in patients

with chronic obstructive pulmonary disease. Rev Med Chil 1999;127 (4):421-428.

- 39. Ramirez-Sarmiento A, Orozco-Levi M, Guell R, Barreiro E, Hernandez N, Mota S, et al. Inspiratory muscle training in patients with chronic obstructive pulmonary disease: structural adaptation and physiologic outcomes. Am J Respir Crit Care Med 2002;166 (11):1491-1497.
- 40. Sánchez Riera H, Montemayor Rubio T, Ortega Ruiz F, Cejudo Ramos P, Del Castillo Otero D, Elias Hernandez T, et al Inspiratory muscle training in patients with COPD: effect on dyspnea, exercise performance, and quality of life. Chest 2001;120(3):748-756.
- 41. Séron P, Riedemann P, Muñoz S, Doussoulin A, Villarroel P, Cea X. Effect of inspiratory muscle training on muscle strength and quality of life in patients with chronic airflow limitation: a randomized controlled trial. Arch Bronconeumol 2005;41(11):601-606.
- 42. Sudo E, Ohga E, Matsuse T, Teramoto S, Nagase T, Katayama H, et al. The effects of pulmonary rehabilitation combined with inspiratory muscle training on pulmonary function and inspiratory muscle strength in elderly patients with chronic obstructive pulmonary disease. Nihon Ronen Igakkai Zasshi 1997;34(11):929-934.
- Villafranca C, Borzone G, Leiva A, Lisboa C. Effect of inspiratory muscle training with an intermediate load on inspiratory power output in COPD. Eur Respir J 1998;11(1):28-33.
- 44. Wanke T, Formanek D, Lahrmann H, Brath H, Wild M, Wagner C, et al. Effects of combined inspiratory muscle and cycle ergometer training on exercise performance in patients with COPD. Eur Respir J 1994;7(12):2205-2211.
- Weiner P, Azgad Y, Ganam R. Inspiratory muscle training combined with general exercise reconditioning in patients with COPD. Chest 1992;102(5):1351-1356.
- 46. Weiner P, Magadle R, Beckerman M, Weiner M, Berar-Yanay N. Comparison of specific expiratory, inspiratory, and combined muscle training programs in COPD. Chest 2003;124(4):1357-1364.
- Weiner P, Magadle R, Beckerman M, Weiner M, Berar-Yanay N. Maintenance of inspiratory muscle training in COPD patients: one year follow-up. Eur Respir J 2004;23(1):61-65.
- 48. Weiner P, Magadle R, Berar-Yanay N, Davidovich A, Weiner M. The cumulative effect of long-acting bronchodilators, exercise, and inspiratory muscle training on the perception of dyspnea in patients with advanced COPD. Chest 2000;118(3):672-678.
- Weiner P, Weiner M. Inspiratory muscle training may increase peak inspiratory flow in chronic obstructive pulmonary disease. Respiration 2006;73(2):151-156.
- Heijdra YF, Dekhuijzen PNR, Herwaarden C. V, Folgering HT. Nocturnal saturation improves by target-flow inspiratory muscle training in patients with COPD. Am J Respir Crit Care Med 1996;153 (1):260-265.
- Lisboa C, Villafranca C, Leiva A, Cruz E, Pertuze J, Borzone G. Inspiratory muscle training in chronic airflow limitation: effect on exercise performance. Eur Respir J 1997;10(3):537-542.
- 52. Wu W, Guan L, Zhang X, Li X, Yang Y, Guo B, et al. Effects of two types of equal-intensity inspiratory muscle training in stable patients with chronic obstructive pulmonary disease: a randomised controlled trial. Respir Med 2017;132:84-91.
- Cooper CB. Desensitization to dyspnea in COPD with specificity for exercise training mode. Int J Chron Obstruct Pulmon Dis 2009;4 (1):33-43.
- Covey MK, Larson JL, Wirtz SE, Berry JK, Pogue NJ, Alex CG, et al. High-intensity inspiratory muscle training in patients with chronic obstructive pulmonary disease and severely reduced function. J Cardiopulm Rehabil 2001;21(4):231-240.
- Mehani SHM. Comparative study of two different respiratory training protocols in elderly patients with chronic obstructive pulmonary disease. Clin Interv Aging 2017;12:1705-1715.

### Respiratory Care $\bullet \bullet Vol \bullet No \bullet$

- Agusti A, Calverley PM, Celli B, Coxson HO, Edwards LD, Lomas DA, et al. Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir Res 2010;11:122.
- Dellweg D, Reissig K, Hoehn E, Siemon K, Haidl P. Inspiratory muscle training during rehabilitation in successfully weaned hypercapnic patients with COPD. Respir Med 2017;123:116-123.
- 58. Dekhuijzen PN, Beek MM, Folgering HT, Van Herwaarden CL. Psychological changes during pulmonary rehabilitation and targetflow inspiratory muscle training in COPD patients with a ventilatory limitation during exercise. Int J Rehabil Res 1990;13(2):109-117.
- Larson JL, Covey MK, Wirtz SE, Berry JK, Alex CG, Langbein WE, et al. Cycle ergometer and inspiratory muscle training in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999;160 (2):500-507.
- Mador MJ, Deniz O, Deniz O, Aggarwal A, Shaffer M, Kufel TJ, Spengler CM. Effect of respiratory muscle endurance training in patients with COPD undergoing pulmonary rehabilitation. Chest 2005;128(3):1216-1224.
- Majewska-Pulsakowska M, Wytrychowski K, Rozek-Piechura K. The role of inspiratory muscle training in the process of rehabilitation of patients with chronic obstructive pulmonary disease. Adv Exp Med Biol 2016;885:47-51.
- 62. Beaumont M, Mialon P, Le Ber-Moy C, Lochon C, Péran L, Pichon R, et al. Inspiratory muscle training during pulmonary rehabilitation in chronic obstructive pulmonary disease: a randomized trial. Chron Respir Dis 2015;12(4):305-312.
- 63. Wang K, Zeng G-Q, Li R, Luo Y-W, Wang M, Hu Y-H, et al. Cycle ergometer and inspiratory muscle training offer modest benefit

compared with cycle ergometer alone: a comprehensive assessment in stable COPD patients. Int J Chron Obstruct Pulmon Dis 2017;12:2655-2668.

- 64. Schultz K, Jelusic D, Wittmann M, Krämer B, Huber V, Fuchs S, et al. Inspiratory muscle training does not improve clinical outcomes in 3week COPD rehabilitation: results from a randomised controlled trial. Eur Respir J 2018;51(1):1702000.
- 65. Beaumont M, Mialon P, Le Ber C, Le Mevel P, Péran L, Meurisse O, et al. Effects of inspiratory muscle training on dyspnoea in severe COPD patients during pulmonary rehabilitation: controlled randomised trial. Eur Respir J 2018;51(1):1701107.
- 66. Laohachai K, Winlaw D, Selvadurai H, Gnanappa GK, d'Udekem Y, Celermajer D, Ayer J. Inspiratory muscle training is associated with improved inspiratory muscle strength, resting cardiac output, and the ventilatory efficiency of exercise in patients with a Fontan circulation. J Am Heart Assoc 2017;6(8):e005750.
- Laoutaris ID, Dritsas A, Brown MD, Manginas A, Kallistratos MS, Degiannis D, et al. Immune response to inspiratory muscle training in patients with chronic heart failure. Eur J Cardiovasc Prev Rehabil 2007;14(5):679-685.
- Plentz RD, Sbruzzi G, Ribeiro RA, Ferreira JB, Dal Lago P. Inspiratory muscle training in patients with heart failure: meta-analysis of randomized trials. Arq Bras Cardiol 2012;99(2):762-771.
- 69. Albuquerque AL, Quaranta M, Chakrabarti B, Aliverti A, Calverley PM. Exercise performance and differences in physiological response to pulmonary rehabilitation in severe chronic obstructive pulmonary disease with hyperinflation. J Bras Pneumol 2016;42(2):121-129.